var title_f21_60_22464="Factitial dermatitis 2";
var content_f21_60_22464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Factitial dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Self-induced purpuric lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22464=[""].join("\n");
var outline_f21_60_22464=null;
var title_f21_60_22465="Spinal cord cross-section";
var content_f21_60_22465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Cross-sectional anatomy of the spinal cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22465=[""].join("\n");
var outline_f21_60_22465=null;
var title_f21_60_22466="Poractant alfa: Pediatric drug information";
var content_f21_60_22466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Poractant alfa: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/13/25811?source=see_link\">",
"    see \"Poractant alfa: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Curosurf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Curosurf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Lung Surfactant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endotracheal: Initial: 2.5 mL/kg/dose (200 mg/kg/dose); may repeat 1.25 mL/kg/dose (100 mg/kg/dose) at 12-hour intervals for up to 2 additional doses; maximum total dose: 5 mL/kg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intratracheal [porcine derived, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Curosurf&reg;: 80 mg/mL (1.5 mL, 3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intratracheal: For intratracheal administration only; suction infant prior to administration; inspect solution to verify complete mixing of the suspension; do not shake; gently turn vial upside-down to obtain uniform suspension; administer intratracheally by instillation through a 5-French end-hole catheter inserted into the infant's endotracheal tube; each dose should be administered as two aliquots, with each aliquot administered into one of the two main bronchi by positioning the infant with either the right or left side dependent; alternatively, it may be administered through a secondary lumen of a dual lumen endotracheal tube as a single dose administered over 1 minute without interrupting mechanical ventilation",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in refrigerator; protect from light; prior to administration, allow to slowly warm to room temperature; artificial warming methods should",
"     <b>",
"      not",
"     </b>",
"     be used; unused, unopened vials warmed to room temperature may be returned to the refrigerator within 24 hours of warming only once; vials are for single use only",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of respiratory distress syndrome (RDS) in premature infants",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F211434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Endotracheal tube blockage, oxygen desaturation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Pulmonary hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Correction of acidosis, hypotension, anemia, hypoglycemia, and hypothermia is recommended prior to administration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rapidly affects oxygenation and lung compliance and should be restricted to a highly supervised use in a clinical setting with immediate availability of clinicians experienced with intubation and ventilatory management of premature infants; if transient episodes of bradycardia and decreased oxygen saturation occur, discontinue the dosing procedure and initiate measures to alleviate the condition; produces rapid improvements in lung oxygenation and compliance that may require immediate reductions in ventilator settings and FiO",
"     <sub>",
"      2",
"     </sub>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pulmonary hemorrhage is a known complication of premature birth and very low birth weight. It has been reported in both clinical trials and postmarketing reports in infants who have received poractant.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous heart rate and transcutaneous O",
"     <sub>",
"      2",
"     </sub>",
"     saturation should be monitored during administration; frequent ABG sampling is necessary to prevent postdosing hyperoxia and hypocarbia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Poractant alfa, an extract of natural porcine lung surfactant, replaces deficient or ineffective endogenous lung surfactant in neonates with respiratory distress syndrome (RDS); surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between air and alveolar surfaces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12717 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22466=[""].join("\n");
var outline_f21_60_22466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211409\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211410\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061248\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444750\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211399\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211387\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061251\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061246\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061250\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211434\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061243\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061242\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299909\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222447\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061247\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061241\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12717\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12717|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/13/25811?source=related_link\">",
"      Poractant alfa: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_60_22467="Gallium nitrate: Drug information";
var content_f21_60_22467=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gallium nitrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/43/1716?source=see_link\">",
"    see \"Gallium nitrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ganite&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium-Lowering Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Initiate I.V. hydration prior to treatment; maintain throughout treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypercalcemia (cancer-related):",
"     </b>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 5 consecutive days; treatment duration may be shortened if normocalcemia is achieved in &lt;5 days. If hypercalcemia is mild and with limited symptoms, 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day may be used.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F175245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate renal impairment (serum creatinine 2 to &le;2.5 mg/dL): There are no dosage adjustment s provided in the manufacturer&rsquo;s labeling; frequent monitoring of renal status is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe renal impairment (serum creatinine &gt;2.5 mg/dL): Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F175226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ganite&trade;: 25 mg/mL (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F175228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer recommends continuous I.V. infusion over 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F175262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, aminophylline, ampicillin/sulbactam, aztreonam, cefazolin, ceftazidime, cimetidine, ciprofloxacin, cladribine, cyclophosphamide, diphenhydramine, docetaxel, etoposide phosphate, filgrastim, fluconazole, furosemide, gemcitabine, granisetron, heparin, hydrocortisone sodium succinate, ifosfamide, magnesium sulfate, mannitol, melphalan, meperidine, mesna, methotrexate, metoclopramide, ondansetron, piperacillin, piperacillin/tazobactam, potassium chloride, ranitidine, sodium bicarbonate, sulfamethoxazole/trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, vancomycin, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, cisplatin, cytarabine, doxorubicin, doxorubicin liposome, etoposide, haloperidol, hydromorphone, lorazepam, morphine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone, dexamethasone sodium phosphate, fluorouracil, imipenem/cilastatin, prochlorperazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptomatic cancer-related hypercalcemia (refractory to adequate hydration)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F175255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema (lower extremity), hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma, confusion, dreams, encephalopathy, fever, hallucinations, hypothermia, lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (&le;79%), serum bicarbonate decreased (40% to 50%), hypocalcemia (38%), respiratory alkalosis (mild)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, positive Cvostek&rsquo;s sign",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic neuritis (&lt;1%), blindness (case report)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Auditory acuity decreased (&lt;1%), tinnitus (&lt;1%), hearing decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased (13%), creatinine increased (13%), acute renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pleural effusion, pulmonary infiltrates, rales, rhonchi",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F175231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe renal dysfunction (serum creatinine &gt;2.5 mg/dL)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F175217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypocalcemia: Treatment may result in mild-to-moderate or asymptomatic hypocalcemia; may require discontinuation of gallium nitrate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Concurrent administration with other nephrotoxic drugs (eg, aminoglycosides, amphotericin B) may increase the risk for renal insufficiency in patients with cancer-related hypercalcemia; discontinue gallium nitrate during treatment with nephrotoxic drugs (monitor serum creatinine and urine output; continue hydration for several days). Discontinue with serum creatinine &gt;2.5 mg/dL.",
"     </b>",
"     BUN and serum creatinine elevations have been observed with gallium nitrate use; establish and maintain adequate hydration with oral and/or I.V. (normal saline) fluids; establish urinary output &ge;2 L/day prior to treatment initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients where aggressive hydration may be poorly tolerated, such as in cardiovascular disease (HF or hypertension) and pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Nephrotoxicity: Discontinue gallium nitrate during treatment with nephrotoxic drugs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F175221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F175223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Gallium nitrate should be used in pregnant women only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F175250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F175233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reactions in the nursing infant, it is recommended to discontinue nursing during treatment or discontinue gallium nitrate.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ganite Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (20 mL): $1200.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F175224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (BUN, serum creatinine); serum calcium (baseline, then daily); serum phosphorus (baseline, then twice weekly); albumin; fluid intake, urine output",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F175216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium resorption from bone by inhibiting osteoclast activity. Gallium nitrate appears to be effective in parathyroid hormone-related protein (PTHrP) and non-PTHrP-associated hypercalcemia.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F175230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of calcium lowering: Calcium begins to decrease within 24-48 hours; normocalcemia achieved within 5-9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Normocalcemia: 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Continuous infusion: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 670 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Continuous infusion: 105 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily renal with no prior metabolism in the liver or kidney",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chitambar CR, \"Gallium Nitrate Revisited,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2003, 30(2 Suppl 5):1-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cvitkovic F, Armand JP, Tubiana-Hulin M, et al, &ldquo;Randomized, Double-Blind, Phase II Trial of Gallium Nitrate Compared With Pamidronate for Acute Control of Cancer-Related Hypercalcemia,&rdquo;",
"      <i>",
"       Cancer J",
"      </i>",
"      , 2006, 12(1):47-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/60/22467/abstract-text/16613662/pubmed\" id=\"16613662\" target=\"_blank\">",
"        16613662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einhorn L, &ldquo;Gallium Nitrate in the Treatment of Bladder Cancer,&rdquo;",
"      <i>",
"       Sem Oncol",
"      </i>",
"      , 2003, 30(2 Suppl 5): 34-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/60/22467/abstract-text/12776258/pubmed\" id=\"12776258\" target=\"_blank\">",
"        12776258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hortobagyi GN, &ldquo;Novel Approaches to the Management of Bone Metastases,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2003, 30(5 Suppl 16):161-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/60/22467/abstract-text/14613037/pubmed\" id=\"14613037\" target=\"_blank\">",
"        14613037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leyland-Jones B, \"Pharmacokinetics and Therapeutic Index of Gallium Nitrate,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1991, 18(4 Suppl 5):16-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/60/22467/abstract-text/1925625/pubmed\" id=\"1925625\" target=\"_blank\">",
"        1925625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leyland-Jones B, &ldquo;Treatment of Cancer-Related Hypercalcemia: The Role of Gallium Nitrate,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2003, 30(2 Suppl 5):13-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/60/22467/abstract-text/12776255/pubmed\" id=\"12776255\" target=\"_blank\">",
"        12776255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Straus DJ, &ldquo;Gallium Nitrate in the Treatment of Lymphoma&rdquo;,",
"      <i>",
"       Sem Oncol",
"      </i>",
"      , 2003, 30(2 Suppl 5):25-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/60/22467/abstract-text/12776257/pubmed\" id=\"12776257\" target=\"_blank\">",
"        12776257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warrell RP Jr, Israel R, Frisone M, et al, &ldquo;Gallium Nitrate for Acute Treatment of Cancer-Related Hypercalcemia. A Randomized, Double-Blind Comparison to Calcitonin,&rdquo;",
"      <i>",
"       Ann Intern Med,",
"      </i>",
"      1988, 108(5):669-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/60/22467/abstract-text/3282463/pubmed\" id=\"3282463\" target=\"_blank\">",
"        3282463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8706 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-113.53.254.124-0961F7E403-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22467=[""].join("\n");
var outline_f21_60_22467=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
" </div>"].join("\n");
var title_f21_60_22468="Common hepatic duct stricture";
var content_f21_60_22468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Common hepatic duct stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram showing a stricture of the common hepatic duct and hepatic duct bifurcation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22468=[""].join("\n");
var outline_f21_60_22468=null;
var title_f21_60_22469="Timolol (systemic): Patient drug information";
var content_f21_60_22469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Timolol (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27287?source=see_link\">",
"     see \"Timolol (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/9/16534?source=see_link\">",
"     see \"Timolol (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Timol&reg;;",
"     </li>",
"     <li>",
"      Nu-Timolol;",
"     </li>",
"     <li>",
"      Teva-Timolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop tremor (essential).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used after a heart attack to stop future heart attacks and lengthen life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop performance anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop rebleeding from esophageal varices in cirrhosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bold or forceful actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by drugs that are used for mood.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to timolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12322 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22469=[""].join("\n");
var outline_f21_60_22469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600176\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024699\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024701\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024700\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024705\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024706\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024708\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024703\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024704\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024709\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024710\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/60/28615?source=related_link\">",
"      Timolol (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30932?source=related_link\">",
"      Timolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25014?source=related_link\">",
"      Timolol (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27287?source=related_link\">",
"      Timolol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/9/16534?source=related_link\">",
"      Timolol (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_60_22470="Methenamine, sodium biphosphate, phenyl salicylate, methylene blue, and hyoscyamine: Drug information";
var content_f21_60_22470=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methenamine, sodium biphosphate, phenyl salicylate, methylene blue, and hyoscyamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/4/38981?source=see_link\">",
"    see \"Methenamine, sodium biphosphate, phenyl salicylate, methylene blue, and hyoscyamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphasal&trade;;",
"     </li>",
"     <li>",
"      Urelle&reg;;",
"     </li>",
"     <li>",
"      Uribel&trade;;",
"     </li>",
"     <li>",
"      Uta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urinary tract symptoms:",
"     </b>",
"     Oral: One tablet 4 times daily (follow by liberal fluid intake)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F194263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urinary tract symptoms:",
"     </b>",
"     Children &gt;6 years: Oral: Dosage must be individualized",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uribel&trade;: Methenamine 118 mg, sodium biphosphate 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uta&reg;: Methenamine 120 mg, sodium biphosphate 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phosphasal&trade;: Methenamine 81.6 mg, sodium biphosphate 40.8 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urelle&reg;: Methenamine 81 mg, sodium biphosphate 40.8 mg, phenyl salicylate 32.4 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptoms of irritative voiding; relief of local symptoms associated with urinary tract infections; relief of urinary tract symptoms caused by diagnostic procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13940382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia, flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention (acute), micturition difficulty, discoloration of urine (blue)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methenamine, hyoscyamine, methylene blue, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Belladonna alkaloid allergy: Use with caution in patients with a history of intolerance to belladonna alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blurred vision: Discontinue use immediately if blurred vision occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dizziness: Discontinue use immediately if dizziness occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylate allergy: Use with caution in patients with a history of intolerance to salicylates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembranous colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tachycardia: Discontinue use immediately if tachycardia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (cardiac arrhythmias, HF, coronary heart disease, mitral stenosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal tract obstruction: Use with caution in patients with gastrointestinal tract obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obstructive uropathy: Use with caution in patients with obstructive uropathy (bladder neck obstruction or prostatic hyperplasia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to potent anticholinergic effects and uncertain effectiveness (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &le;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urine discoloration: May cause urinary discoloration (blue).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Methenamine may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May diminish the therapeutic effect of Methenamine. Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: Methenamine may enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination. Methenamine and hyoscyamine cross the placenta. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F194259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methenamine and hyoscyamine are excreted in breast milk. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Uribel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     118 mg (100): $241.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (UTA Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $371.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Phosphasal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81.6 mg (100): $118.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Urelle Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (90): $465.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Utira-C Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81.6 mg (100): $158.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Utrona-C Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81.6 mg (100): $128.69",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/60/22470/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9938 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22470=[""].join("\n");
var outline_f21_60_22470=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194254\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194267\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194257\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194263\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194258\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194248\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194239\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194249\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13940382\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194265\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194251\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194241\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299686\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194244\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194246\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287065\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194259\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287067\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422266\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9938\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9938|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/4/38981?source=related_link\">",
"      Methenamine, sodium biphosphate, phenyl salicylate, methylene blue, and hyoscyamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_60_22471="Decision analysis";
var content_f21_60_22471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Decision analysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22471/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22471/contributors\">",
"     Mark S Roberts, MD, MPP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22471/contributors\">",
"     Joel Tsevat, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22471/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22471/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22471/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22471/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/60/22471/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decision analysis is a quantitative evaluation of the outcomes that result from a set of choices in a specific clinical situation. With the exception of the word",
"    <strong>",
"     quantitative",
"    </strong>",
"    , this definition is no different from the clinical decision making process conducted by clinicians every day. When faced with a particular problem, clinicians develop an array of possible actions ranging from doing nothing, to obtaining more information by performing diagnostic tests, to recommending various therapeutic strategies. This process is often implicit and occurs in the context of internal algorithms and heuristics (mental shortcuts) that the clinician has developed and acquired over time. Decision analysis, by requiring a specific model structure and assessment of the various likelihoods and values of the outcomes, makes the decision process explicit and much more amenable to examination, discussion, and intellectual challenge.",
"   </p>",
"   <p>",
"    Decision models are often used as an analytic tool to conduct cost-effectiveness analyses since decision analysis methodology can be used to find the expected value of most any outcome. Cost-effectiveness analysis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF PROBLEMS APPROPRIATE FOR DECISION ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of clinical problems appropriate for decision analysis is vast. The two major requirements for its use include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The problem focuses upon a specific decision that must be made",
"     </li>",
"     <li>",
"      There is a tradeoff involved in the decision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    \"Tradeoff\" means that one of the choices considered should not be unambiguously superior. As an example, a diagnostic test might carry some risk, but the tradeoff is more appropriate therapy when treatment is directed by the results of that test.",
"   </p>",
"   <p>",
"    The scope of the problem should be manageable. Asking, \"Should patients with HIV be treated with antiretroviral therapy?\" poses a question so broad and complex that it is unanswerable. In contrast, a question such as, \"At what levels of viral load and CD4 count should one initiate therapy?\" is sufficiently specific to be amenable to decision analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/1\">",
"     1",
"    </a>",
"    ]. This specific question illustrates another characteristic of problems appropriate for decision analysis: there should be debate or uncertainty regarding the best choice. It is unlikely that decision analysis would be useful if it addresses the exact question already answered definitively by a randomized controlled trial.",
"   </p>",
"   <p>",
"    Questions relating to clinical decisions that do not have direct answers in the literature are remarkably common. One may be faced with a patient who is significantly older or has more comorbidities than the study population in a published trial or who has a set of unique attributes that make the direct application of results from a published study problematic. In general, decision analyses have been developed to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assist in clinical decision making for a specific individual patient",
"     </li>",
"     <li>",
"      Estimate optimal strategies for classes of patients with specific clinical characteristics in given situations",
"     </li>",
"     <li>",
"      Link estimates of both clinical and economic outcomes (cost-effectiveness analysis) to help inform health policy questions",
"     </li>",
"     <li>",
"      Provide estimates of expected outcomes in situations where classical methods such as randomized trials are either impossible or impractical",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several advantages of using decision analysis to investigate options involving a single patient [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/2\">",
"     2",
"    </a>",
"    ]. Placing the problem in an explicit, analytic context forces clinicians to make their assumptions clear, and the presence of a structured model rapidly focuses clinical disagreements. Decision analyses can directly incorporate issues regarding quality of life and how the particular patient values various outcomes. As an example, if possible death in the near-term is the trade-off for a potential cure, then maximizing life expectancy may not be the most important outcome for a terminally ill patient who wants to live to witness a grandchild's graduation from college several months hence. Such individual patient preferences can be incorporated directly into decision analyses by altering the value of the various outcomes.",
"   </p>",
"   <p>",
"    Decision analyses are performed more commonly to evaluate the appropriate strategy for a class of patients identified by a set of clinical characteristics. Often this will involve combining data from a variety of different sources to provide a comprehensive analysis of the problem. An example of such a decision analysis is an analysis weighing the risks and benefits of prophylactic mastectomy and oophorectomy for patients with BRCA1 or BRCA2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/3\">",
"     3",
"    </a>",
"    ]. The model combined several kinds of data, including baseline cancer incidence, the risks of the various procedures, and the estimates of the increased risks of ovarian and breast cancer for women with the mutations. The analysis demonstrated, using the best available data at the time, that life expectancy for women who carry those mutations was increased by as much as 5.3 years with prophylactic mastectomy and by as much as 1.7 years with prophylactic oophorectomy.",
"   </p>",
"   <p>",
"    Decision analysis can also be used to provide estimates of risks and benefits for groups of patients with characteristics somewhat different from patients studied in previous randomized controlled trials. This application was exemplified by Krumholz and co-workers, who constructed a decision model of thrombolytic therapy for elderly patients with myocardial infarction (see Example below) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/4\">",
"     4",
"    </a>",
"    ]. Their paper also illustrates how a decision analysis of a clinical problem can be blended with economic outcomes to produce a cost-effectiveness analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONDUCTING A DECISION ANALYSIS OF A SPECIFIC PROBLEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developing and constructing a decision analysis follows a logical series of steps. Problems or errors in any step can alter the eventual results; thus, proper adherence to each of these steps is important both from the view of a researcher conducting an analysis and a clinician interpreting the results of a published study. Throughout the remainder of this topic review, the basic techniques of decision analysis are described in a primer-based style, with no assumption of prior knowledge or experience. In addition, we have annotated and explained the decision analysis by Krumholz and colleagues in an example below, which is linked at each step to illustrate how these methods were applied in a published decision analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/4\">",
"     4",
"    </a>",
"    ]. For a more detailed introduction to decision analysis, the reader is referred to a series of introductory articles in Medical Decision Making [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Step 1: Frame the question",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of defining the scope and boundaries of the particular clinical situation to be analyzed is similar to developing selection criteria for a randomized controlled trial. The purpose is to define the particular population of patients, conditions, and intervention strategies that are appropriate to the analysis.",
"   </p>",
"   <p>",
"    One of the most important decisions to be made in a decision analysis is the",
"    <strong>",
"     perspective",
"    </strong>",
"    from which the analysis is to be conducted. As an example, a decision analysis conducted from the point of view of an individual patient may look different when analyzed from society's point of view, where secondary effects on others in the population (eg, from transmission of an infectious disease) would need to be included. Examples of multiple perspectives can be found in decision analyses of the decision to use preventive therapy in patients with latent tuberculosis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time horizon of the analysis needs to be specified and be consistent with the clinical reality of the condition. A time horizon of one month, for example, would be inappropriate for a decision analysis of a cholesterol lowering medication since gains in survival may not be realized for years. On the other hand, a decision analysis of different treatments for urinary tract infection might not need to consider outcomes beyond one or two months after treatment. In general, the time frame should match the natural history of the disease process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Step 2: Structure the clinical problem",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structuring the problem simply means constructing a decision model that represents the relevant components of the problem. The mathematical representation of a decision model is called a",
"    <strong>",
"     decision tree",
"    </strong>",
"    and is composed of several discrete elements. Elements combined into trees contain an arbitrary amount of detail. Virtually any decision can be modeled, but it is important that the choices considered are realistic. As an example, a decision analysis examining bypass surgery versus medical therapy but ignoring percutaneous coronary intervention might be inappropriate.",
"   </p>",
"   <p>",
"    There is constant tension between increasing the level of detail to be as clinically realistic as possible versus the feasibility of model construction, validation, and presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/12\">",
"     12",
"    </a>",
"    ]. The more detail desired, the more difficult the model is to construct, validate, and present. However, the less detailed the analysis and the greater the number of simplifying assumptions, the more vulnerable is the analysis to attack for lacking clinically meaningful elements.",
"   </p>",
"   <p>",
"    All decision trees begin with a decision node, which represents the decision to be made (",
"    <a class=\"graphic graphic_figure graphicRef80928 \" href=\"UTD.htm?8/42/8877\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82124 \" href=\"UTD.htm?22/58/23470\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Figure 1 illustrates a decision with two options, Choice 1 and Choice 2, representing a generic clinical decision. Such a decision could represent the choice between medical and surgical therapy for a particular condition; empiric treatment for a disease versus diagnostic testing; or different follow-up intervals after resection of a cancer.",
"     </li>",
"     <li>",
"      Following a decision node is one or more chance nodes. In this example, Outcome 1 and Outcome 2 are possible consequences of Choice 1, and Outcome 3 and Outcome 4 are possible consequences of Choice 2. Each branch of a chance node is characterized by a probability (p1 through p4), which represents the likelihood that the particular event will occur. The sum of all probabilities at a chance node must equal 1.0.",
"     </li>",
"     <li>",
"      At the end of each branch is a terminal node, which represents a state of health or outcome that results from traversing a particular path through the tree. As an example, if Choice 1 represents a surgical intervention, Outcome 1 might be surgical death, and therefore Value 1 (or V1, which might represent life expectancy) would be the value assigned to immediate death, which is by convention 0.0.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    See below for a more detailed example.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Step 3: Estimate the relevant probabilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a decision tree has been structured, the numeric values of the various probabilities need to be determined. There are many sources of data that can be used to make these determinations. Although there is a generally accepted hierarchy of study quality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/13\">",
"     13",
"    </a>",
"    ], such ratings are not always useful for decision analysis since the particular study type may not be conducive to estimating a given parameter. As an example, a randomized controlled trial is an excellent source for comparing one therapy versus another, but it is a poor source of data regarding the incidence of a particular disease. Thus, it is important to tailor the data source to the type of data required (",
"    <a class=\"graphic graphic_table graphicRef70046 \" href=\"UTD.htm?32/32/33291\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is rarely the case that all of the data needed to parameterize a decision model can be found in a single study. If that were true, it would be likely that the question being asked had already been answered.",
"   </p>",
"   <p>",
"    The sources used to estimate probabilities need to take into consideration potential differences in characteristics of populations between published trials and the population of interest to the decision analyst. As an example, carotid endarterectomy was found to be beneficial in patients with asymptomatic carotid stenosis in a study in which the operative mortality rate was 3.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/14\">",
"     14",
"    </a>",
"    ]. The local rate should be used in the analysis if it is different from the published rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Step 4: Estimate the values of the outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structure of the problem defines the specific outcome measure to be used. As noted above, life expectancy is not likely to be a relevant outcome for an analysis of different treatment strategies for urinary tract infection. In contrast, if death is a possible outcome of one or more strategies, life expectancy would be an appropriate outcome measure. The most important aspect in assigning outcomes is that they be measured in the same units across all branches.",
"   </p>",
"   <p>",
"    A useful feature of decision analysis is that a given model can be evaluated using different outcome measures. As an example, in addition to survival, the investigator may want to track the effect of different therapies upon the rate of stroke, myocardial infarction, pulmonary embolization, etc., across various treatment options. The decision model can be analyzed using any of those outcomes.",
"   </p>",
"   <p>",
"    It is intuitively obvious that a year of life in full health is not the same as a year with severe angina or a year of life following a stroke or an amputation. Patients place different values on those health states and are willing to accept risks (undergo operations, take medications with side effects) to avoid them. In decision analyses, one can consider quality of life and length of life simultaneously.",
"   </p>",
"   <p>",
"    The important attribute of quality of life measures for decision models is that they allow quantitative comparisons between different health states. In other words, quality of life adjustments for decision models must be able to make comparisons of the form: \"One year of life with a stroke is worth X percent of a year of life in full health.\" When measured in this manner, decision analyses produce estimates of quality-adjusted life years (QALYs). These methods are summarized in a classic review [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/15\">",
"     15",
"    </a>",
"    ]. Methods to incorporate quality of life, although somewhat controversial, are available [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Step 5: Analyze the tree: The mechanics of the analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"answer\" to a decision analysis problem is the strategy that maximizes the expected value of the outcome. As an example, if the outcome of interest were life expectancy, the result of a decision analysis would be of the form: \"the average life expectancy with strategy A is 10.2 years versus 9.8 years with strategy B; therefore strategy A is the optimal strategy.\"",
"   </p>",
"   <p>",
"    These \"expected values\" or \"expected utilities\" are determined by recursive evaluation of the tree (known as averaging out and folding back) from right to left, replacing each chance node with the expected value of the combination of branches that arise from that chance node. The value of each branch at a decision node is the arithmetic average of the branches that follow. For the simple tree in the figure (",
"    <a class=\"graphic graphic_figure graphicRef80928 \" href=\"UTD.htm?8/42/8877\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Expected value of Choice 1 = (p1*V1) + (p2*V2)",
"     </li>",
"     <li>",
"      Expected value of Choice 2 = (p3*V3) + (p4*V4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More concretely, the figure illustrates the calculation for hypothetical probabilities and life expectancies (",
"    <a class=\"graphic graphic_figure graphicRef64670 \" href=\"UTD.htm?36/29/37341\">",
"     figure 3",
"    </a>",
"    ). Such a tree might represent the choice between two therapies, one with little difference between its possible outcomes (Choice 1) and the other offering a chance of longer life at the risk of a shorter life (Choice 2). In this example, Choice 2 is the preferred strategy in terms of life expectancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Step 6: Test the model's assumptions: Sensitivity analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results obtained from a decision analysis depend upon the accuracy of the data used to estimate the probabilities and outcomes. It is rarely the case that estimates are known with complete certainty; even in data from very large population-based studies, estimates of mortality and effectiveness are couched in confidence limits.",
"   </p>",
"   <p>",
"    One of the major advantages of decision analysis models is their ability to rapidly test their assumptions and input data. As an example, in referring to the hypothetical example in Figure 2, suppose the life expectancy estimate of 10 years for patients who experienced Outcome 1 came from a relatively small study, and the confidence limits on life expectancy ranged from 8 to 12 years. That range could be used to recalculate the model several times in order to examine whether or not such differences would change which strategy was optimal (",
"    <a class=\"graphic graphic_table graphicRef71714 \" href=\"UTD.htm?19/57/20379\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The table represents a one-way sensitivity analysis since it varies the value of only a single variable (",
"    <a class=\"graphic graphic_table graphicRef71714 \" href=\"UTD.htm?19/57/20379\">",
"     table 2",
"    </a>",
"    ). More than one parameter can be varied, producing two-, three-, and multi-way sensitivity analyses that relate the expected value of the choices to simultaneous variations in the values of several variables.",
"   </p>",
"   <p>",
"    Sensitivity analysis is also a helpful tool in constructing and validating decision models. The model's answer can be compared with the \"true\" answer to validate the model structure by evaluating a tree using parameters for which the result is known a priori. As an example, in a choice between a more effective (but riskier) surgical therapy and a less effective (but safer) medical therapy, a sensitivity analysis that postulated a zero mortality rate for the surgical intervention should advocate the surgical arm since there would be no downside risk. If the model did not indicate that the surgical arm was preferred, an error or \"bug\" in the model would likely be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Step 7: Interpret the results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpreting the results of a decision analysis is often the most complicated task. Unlike other experimental designs or study types, it is often not the explicit result from a decision analysis that becomes its most important contribution to decision making. Rather, the ability of a decision analysis to explore how the optimal strategy in a particular clinical situation changes with variation in assumptions (and therefore to identify areas for further data needs) is often one of the most powerful attributes of this type of analysis.",
"   </p>",
"   <p>",
"    Several conditions must be met before the results can be incorporated into day-to-day practice [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relevant competing strategies must be included",
"     </li>",
"     <li>",
"      All clinically relevant outcomes given those strategies must be described",
"     </li>",
"     <li>",
"      The data used for calibration (both probabilities and outcomes) must be acquired and summarized in a clear and reasonable manner",
"     </li>",
"     <li>",
"      Appropriate sensitivity analyses must be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, the consumer of a decision analysis should examine several details of an analysis prior to using the results to change practice.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient population should closely match the patients seen by the clinician. A decision analysis exploring coronary artery bypass graft versus percutaneous coronary intervention in young male patients with chronic stable angina probably will not inform the same decision as in elderly women with crescendo angina.",
"     </li>",
"     <li>",
"      The reader needs to assess the strength of the result. Decision analyses do not contain statistical indicators such as p-values. Thus, one relies on the sensitivity analysis to indicate whether outcomes change over appropriate ranges of relevant variables. If sensitivity analyses indicate that the optimal choice is strongly dependent upon a given parameter, one should try to develop accurate measures of the parameter estimate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXTENSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple node and branch decision trees can be used to develop models of arbitrary complexity, but the methodology is not particularly well-suited to modeling events that occur repetitively over time, or to analyzing interventions that alter the risk of future events. Such problems are more appropriately structured using methods that explicitly include the element of time. One such technique is the Markov process. Markov models are an extremely powerful complement to decision analysis for expanding the types and complexity of clinical situations that can be effectively analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/19\">",
"     19",
"    </a>",
"    ]. More recently, complex models of underlying physiologic processes have been incorporated into decision models, allowing a clinically realistic representation of the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decision models are often used as the analytic \"engine\" to conduct cost-effectiveness analyses since decision analysis methodology can be used to find the expected value of most any outcome. Cost-effectiveness analysis is a methodology that examines the simultaneous effect of different strategies upon clinical and economic outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .) By including both costs and clinical effects in one model, analyses can provide estimates of the cost per year of life saved, the cost per quality-adjusted life year saved, etc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EXAMPLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of thrombolytic therapy in elderly patients with myocardial infarction (MI) provides a good example of how decision analysis can be used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Step 1: Frame the question",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of thrombolytic agents in acute MI have demonstrated benefit in the patient populations studied, but the indications for their use in the elderly have been controversial. Noting that no trial had directly addressed this issue, one group performed a decision analysis to address the problem [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/4\">",
"     4",
"    </a>",
"    ]. Their approach represents a common use of decision analysis: extending tried and true therapies into populations somewhat dissimilar from those initially studied.",
"   </p>",
"   <p>",
"    The thrombolysis issue has several characteristics that make it appropriate for decision analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is a specific choice (to give thrombolytic therapy or not)",
"     </li>",
"     <li>",
"      There are accurate data on the characteristics and outcomes of MIs in the elderly",
"     </li>",
"     <li>",
"      There is strong evidence of efficacy in certain study populations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following paragraphs describe the decision analysis of Krumholz and colleagues [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/4\">",
"     4",
"    </a>",
"    ]. The published version of this analysis did not include a figure of the tree, but we present the tree so that the reader may follow and replicate the analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Step 2: Structure the clinical problem",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision tree models two mutually exclusive strategies: whether to give thrombolytic therapy to an elderly patient with acute MI or provide only supportive care (",
"    <a class=\"graphic graphic_figure graphicRef77445 \" href=\"UTD.htm?5/35/5694\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If thrombolysis is chosen, the patient may experience a complication of therapy (eg, cerebral hemorrhage). In this analysis, complications of thrombolysis are assumed to be equivalent to death. However, because a cerebral hemorrhage may not always be tantamount to death, their assumption biases the analysis against thrombolysis by making the complications worse than they might actually be.",
"     </li>",
"     <li>",
"      The diagnostic criteria for MI are not perfect. Thus, some patients given thrombolytics have actually not had an MI (false positives). For this reason, a chance node representing actual MI versus no MI follows the",
"      <span class=\"nowrap\">",
"       complication/no",
"      </span>",
"      complication node.",
"     </li>",
"     <li>",
"      The patient may die or survive whether or not she has an MI, although the likelihood of death will be much higher with MI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The no thrombolysis strategy looks the same structurally except for the absence of the",
"    <span class=\"nowrap\">",
"     complication/no",
"    </span>",
"    complication branch, since no drug is administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Step 3: Estimate the relevant probabilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structure of the tree and the number of branches at chance nodes define the probabilities required to \"parameterize\" the tree. In this model, estimates of the probability of MI, the mortality rates with and without infarction, and the efficacy and risks of thrombolytic therapy are required (",
"    <a class=\"graphic graphic_table graphicRef81073 \" href=\"UTD.htm?21/1/21531\">",
"     table 3",
"    </a>",
"    ). The majority of the data for this analysis came from published trials including the Groupo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardio (GISSI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/21\">",
"     21",
"    </a>",
"    ]) and the Second International Study of Infarct Survival (ISIS-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/22\">",
"     22",
"    </a>",
"    ]) trials. Other data were collected from the literature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Step 4: Estimate the values of the outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The values at the end of each terminal node for the basic analysis are simply the value of surviving (set to 1) or dying (0) in the hospital. The expected value of each branch will be the average probability of in-hospital survival for a cohort of patients treated under that strategy (thrombolysis or no thrombolysis).",
"   </p>",
"   <p>",
"    The authors also needed to estimate the number of years of life saved and the costs of the interventions for the purposes of also conducting a cost-effectiveness analysis (beyond the scope of this topic review). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .) They obtained these values from an existing cardiovascular risk prediction model, the Coronary Heart Disease Policy Model [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/23\">",
"     23",
"    </a>",
"    ]. As an example, they estimated that a 70-year-old patient would have a life expectancy of 5.5 years after MI. For calculating average life expectancy (rather than probability of survival) under each strategy, the specific life expectancies for each outcome would be inserted in their appropriate terminal nodes, with the value of death remaining at zero.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Step 5: Analyze the tree (average out/fold back)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tree is analyzed using the standard averaging-out and folding back approach described above. The tree is folded back from right to left, and the average value at each chance node is calculated (",
"    <a class=\"graphic graphic_figure graphicRef78049 \" href=\"UTD.htm?28/30/29166\">",
"     figure 5",
"    </a>",
"    ). Given the baseline assumptions provided in Figure 4, the expected value of complication-free survival is 0.7864 for the thrombolytic arm versus 0.7559 for the standard therapy strategy.",
"   </p>",
"   <p>",
"    The results can also be presented in two other forms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The number needed to treat to save one additional life",
"     </li>",
"     <li>",
"      Life expectancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to calculate life expectancies, one would need to know the life expectancy after MI for a patient of a given age, estimated in this study to be 5.5 years for a 70-year-old male [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/4\">",
"     4",
"    </a>",
"    ]. Using standard life expectancy tables for survival without MI, the relevant life expectancies could be entered as the values of the terminal node, and the analysis repeated to find the expected life expectancy for each strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Step 6: Test assumptions (sensitivity analysis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have provided a simple one-way sensitivity analysis as an introduction, changing only the probability of a fatal complication of thrombolytic therapy over a reasonable range of values (0 to 6 percent). This can be seen in a figure (",
"    <a class=\"graphic graphic_figure graphicRef70966 \" href=\"UTD.htm?40/6/41069\">",
"     figure 6",
"    </a>",
"    ). As expected, the probability of surviving under the thrombolysis strategy decreases as the risk of fatal complication rises. At a probability of fatal complication greater than 0.042 (the so-called \"threshold\"), the thrombolytic strategy becomes inferior to the no-thrombolytic strategy.",
"   </p>",
"   <p>",
"    The published paper presents several examples of two-way sensitivity analyses, where two variables (probability of MI and effectiveness of thrombolytic therapy) are varied simultaneously to determine when thrombolytic therapy is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22471/abstract/4\">",
"     4",
"    </a>",
"    ].&nbsp;All of the analyses demonstrated that for reasonable ranges of values surrounding their baseline estimates, thrombolysis remained the preferred strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Step 7: Interpret the results",
"    </span>",
"    &nbsp;&mdash;&nbsp;This analysis has most of the features of a sound decision analysis. For patients presenting with suspected MI, the model presents two options: thrombolysis versus no thrombolysis. One could question why primary percutaneous coronary intervention was not considered, as this option has been included in many of the MI interventional studies. The data used to calibrate the model come from several large trials and the outcomes modeled were reasonable, although one could have modeled minor complications as well. Several sensitivity analyses were performed, all indicating that the results were quite robust.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decision analysis is a quantitative evaluation of the outcomes that result from a set of choices in a specific clinical situation. With the exception of the word quantitative, this definition is no different from the clinical decision making process conducted by clinicians every day. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The range of clinical problems appropriate for decision analysis is vast. The two major requirements for its use include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The problem focuses upon a specific decision that must be made",
"     </li>",
"     <li>",
"      There is a tradeoff involved in the decision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Types of problems appropriate for decision analysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decision analysis is performed using estimates of probabilities of events and values placed on outcomes. These outcomes may include patient values such as quality adjusted life years or rates of events such as mortality. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Conducting a decision analysis of a specific problem'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/1\">",
"      Braithwaite RS, Roberts MS, Chang CC, et al. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med 2008; 148:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/2\">",
"      Plante DA, Kassirer JP, Zarin DA, Pauker SG. Clinical decision consultation service. Am J Med 1986; 80:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/3\">",
"      Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/4\">",
"      Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/5\">",
"      Detsky AS, Naglie G, Krahn MD, et al. Primer on medical decision analysis: Part 1--Getting started. Med Decis Making 1997; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/6\">",
"      Detsky AS, Naglie G, Krahn MD, et al. Primer on medical decision analysis: Part 2--Building a tree. Med Decis Making 1997; 17:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/7\">",
"      Naglie G, Krahn MD, Naimark D, et al. Primer on medical decision analysis: Part 3--Estimating probabilities and utilities. Med Decis Making 1997; 17:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/8\">",
"      Krahn MD, Naglie G, Naimark D, et al. Primer on medical decision analysis: Part 4--Analyzing the model and interpreting the results. Med Decis Making 1997; 17:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/9\">",
"      Naimark D, Krahn MD, Naglie G, et al. Primer on medical decision analysis: Part 5--Working with Markov processes. Med Decis Making 1997; 17:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/10\">",
"      Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis 1988; 137:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/11\">",
"      Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/12\">",
"      Roberts MS. The power and pitfalls of simplifying assumptions. Med Decis Making 1997; 17:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/13\">",
"      Boudreau TJ, Last JM, Poole PE, Sackett DL. The National Health Grant Health Care Evaluation Seminars. Can J Public Health 1973; 64:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/14\">",
"      Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/15\">",
"      Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987; 40:593.",
"     </a>",
"    </li>",
"    <li>",
"     Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine, Oxford University Press, New York 1996. p.82.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/17\">",
"      Richardson WS, Detsky AS. Users' guides to the medical literature. VII. How to use a clinical decision analysis. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1995; 273:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/18\">",
"      Richardson WS, Detsky AS. Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? Evidence Based Medicine Working Group. JAMA 1995; 273:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/19\">",
"      Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/20\">",
"      Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005; 143:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/21\">",
"      Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/22\">",
"      Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22471/abstract/23\">",
"      Weinstein MC, Coxson PG, Williams LW, et al. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987; 77:1417.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2758 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22471=[""].join("\n");
var outline_f21_60_22471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF PROBLEMS APPROPRIATE FOR DECISION ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONDUCTING A DECISION ANALYSIS OF A SPECIFIC PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Step 1: Frame the question",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Step 2: Structure the clinical problem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Step 3: Estimate the relevant probabilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Step 4: Estimate the values of the outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Step 5: Analyze the tree: The mechanics of the analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Step 6: Test the model's assumptions: Sensitivity analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Step 7: Interpret the results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXTENSIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EXAMPLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Step 1: Frame the question",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Step 2: Structure the clinical problem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Step 3: Estimate the relevant probabilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Step 4: Estimate the values of the outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Step 5: Analyze the tree (average out/fold back)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Step 6: Test assumptions (sensitivity analysis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Step 7: Interpret the results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2758\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2758|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/42/8877\" title=\"figure 1\">",
"      Basic decision tree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/58/23470\" title=\"figure 2\">",
"      Elements of decision analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/29/37341\" title=\"figure 3\">",
"      Decision tree example",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/35/5694\" title=\"figure 4\">",
"      Decision tree for thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/30/29166\" title=\"figure 5\">",
"      Analysis of thrombolysis tree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/6/41069\" title=\"figure 6\">",
"      Sensitivity analysis thrombolys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2758|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/32/33291\" title=\"table 1\">",
"      Sources of data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/57/20379\" title=\"table 2\">",
"      One way sensitivity analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/1/21531\" title=\"table 3\">",
"      Probabilities for thrombolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_60_22472="Overview of congenital anomalies of the kidney and urinary tract (CAKUT)";
var content_f21_60_22472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22472/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22472/contributors\">",
"     Aoife M Waters, MD, PhD FRCPCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22472/contributors\">",
"     Norman D Rosenblum, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22472/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22472/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22472/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22472/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22472/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/60/22472/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies of the kidney and urinary tract (CAKUT) constitute approximately 20 to 30 percent of all anomalies identified in the prenatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the congenital anomalies of the kidney and urinary tract (CAKUT) is presented here. The antenatal screening and postnatal evaluation of infants with CAKUT and specific disorders are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=see_link\">",
"     \"Congenital ureteropelvic junction obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1479?source=see_link\">",
"     \"Primary megaureter in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=see_link\">",
"     \"Ectopic ureter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28487?source=see_link\">",
"     \"Renal ectopic and fusion anomalies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies of the kidney and urinary tract (CAKUT) represent a broad range of disorders that result from the following abnormal renal developmental processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malformation of the renal parenchyma resulting in failure of normal nephron development as seen in renal dysplasia, renal agenesis, renal tubular dysgenesis, and polycystic renal diseases.",
"     </li>",
"     <li>",
"      Abnormalities of embryonic migration of the kidneys as seen in renal ectopy (eg, pelvic kidney) and fusion anomalies, such as horseshoe kidney.",
"     </li>",
"     <li>",
"      Abnormalities of the developing urinary collecting system as seen in duplicate collecting systems, posterior urethral valves, and ureteropelvic junction obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Defects can be bilateral or unilateral, and different defects often coexist in an individual child.",
"   </p>",
"   <p>",
"    Because CAKUT play a causative role in 30 to 50 percent of cases of end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/2\">",
"     2",
"    </a>",
"    ], it is important to diagnose and initiate therapy to minimize renal damage, prevent or delay the onset of ESRD, and provide supportive care to avoid complications of ESRD. Patients with malformations with a reduction in kidney numbers or size are the most likely to have a poor renal prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal embryologic development of the kidney occurs in three stages (",
"    <a class=\"graphic graphic_figure graphicRef68500 \" href=\"UTD.htm?12/41/12948\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pronephros &ndash; Transient rudimentary and nonfunctioning system that begins in the fourth week of gestation (ie, day 22) and disappears by end of the fourth week (ie, day 28). Degeneration of the pronephros is required for normal kidney development.",
"     </li>",
"     <li>",
"      Mesonephros &ndash; Derived from the intermediate mesoderm by day 26 and by the 5th week develop into 20 paired tubules that produce small amounts of urine. The mesonephros ultimately fuses with the cloaca and contributes to the formation of the urinary bladder, and in the male the ducts and some tubules contribute to the formation of the male genital system.",
"     </li>",
"     <li>",
"      Metanephros &ndash; The metanephros, which is composed of the metanephric mesenchyme and ureteric bud epithelium (caudal portion of the mesonephric duct), is the last stage of renal development and forms the permanent kidney beginning at the 5th week of gestation. Renal metanephric development occurs as a result of co-expression of many genes in the ureteric bud and metanephric mesenchyme that induce organogenesis resulting in the formation of the nephrons and the collecting system [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reciprocal inductive interactions between the metanephric mesenchyme (metanephros) and the ureteric epithelium are dependent upon a number of signaling and transcription factors, including Gdnf (glial-cell-line-derived neurotrophic factor) and its cognate receptor complex,",
"    <span class=\"nowrap\">",
"     RET/GFRa",
"    </span>",
"    1, Osr1, Eya-1, Foxc1, Pax2, Gdf11, Sall1, Six1, BMP4 and WT1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Investigation utilizing molecular genetics has demonstrated that renal malformation results from defects in genes that encode these signaling and transcription factors (",
"    <a class=\"graphic graphic_table graphicRef52772 \" href=\"UTD.htm?16/40/17037\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]&nbsp;. Environmental factors, such as prenatal exposure to teratogens, can also disrupt renal morphogenesis resulting in CAKUT.",
"   </p>",
"   <p>",
"    The metanephros is first detected at five to six weeks of gestation and begins to function at 6 to 10 weeks of gestation, with urine production beginning at nine weeks of gestation. The metanephros is initially positioned in the pelvis opposite the sacral somites and migrates from its caudal position, reaching its permanent location in the lumbar region at the eighth week of gestation.",
"   </p>",
"   <p>",
"    The bladder develops from a separate, but contiguous, structure termed the urogenital sinus. The bladder is present in fetuses with renal agenesis, but is empty because of absent urine production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall rate of CAKUT in live and stillborn infants is 0.3 to 1.6 per 1000 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The incidence is higher in offspring with a family history of CAKUT, and maternal history of either renal disease or diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of all antenatal renal anomalies, the most frequent abnormality is hydronephrosis, (ie, upper urinary tract dilatation). The prevalence of different CAKUT is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef75351 \" href=\"UTD.htm?0/25/413\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/11\">",
"     11",
"    </a>",
"    ]. Renal malformations are associated with non-renal congenital anomalies in about 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/11\">",
"     11",
"    </a>",
"    ]. A combination of CAKUT and non-renal anomalies are found in more than 200 described syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RENAL PARENCHYMAL MALFORMATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malformations of the renal parenchyma result in failure of normal nephron development as seen in renal dysplasia, renal agenesis, renal tubular dysgenesis, multicystic dysplasia, and polycystic kidney disease.",
"   </p>",
"   <p>",
"    The pathogenesis of renal parenchymal malformations is thought to be multifactorial involving genetic and environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/10,17-20\">",
"     10,17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic factors &ndash; Several genes have been implicated in the pathogenesis of renal malformations (",
"      <a class=\"graphic graphic_table graphicRef52772 \" href=\"UTD.htm?16/40/17037\">",
"       table 1",
"      </a>",
"      ). As examples, renal hypodysplasia is associated with mutations in genes expressed during kidney development including EYA1 and SIX1 (branchio-oto-renal syndrome), FRAS1 (Fraser syndrome), PAX2 (renal-coloboma syndrome), SALL1 (Townes-Brocks syndrome) and TCF2 (renal cysts and diabetes mellitus) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/21\">",
"       21",
"      </a>",
"      ]. Polycystic kidney diseases are genetic disorders that result in abnormal terminal epithelial differentiation. The severity and type of renal malformation varies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10935?source=see_link&amp;anchor=H10#H10\">",
"       \"Renal hypoplasia\", section on 'Genetic mutations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Environmental factors &ndash; Environmental effects include exposure to teratogens and nutritional deficiencies. As an example, prenatal exposure to angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) have been associated with juxtaglomerular hyperplasia, diminished or absent differentiation of proximal convoluted tubules, and increased cortical and medullary fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. The proposed mechanism for the teratogenic effect of these medications is interference of the normal upregulation of the renin-angiotensin system during renal development. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Animal models have demonstrated that vitamin A deficiency is associated with urogenital malformations and renal hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/22\">",
"     22",
"    </a>",
"    ]. Additional data suggest that vitamin A plays a significant role in the signaling of ureteric bud branching and the development of the ureteric-bladder connection during embryogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, vitamin A deficiency would disrupt this process resulting in CAKUT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal hypoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple renal hypoplasia, which consists of a lower number of structurally normal nephrons, is a distinct entity separate from renal dysplasia containing renal parenchymal malformations. Although it remains unknown what causes renal hypoplasia, genetic determinants are thought to play a role.",
"   </p>",
"   <p>",
"    The clinical diagnosis of renal hypoplasia is suggested when all of the following criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduction of renal size by 2 standard deviations for the mean size by age",
"     </li>",
"     <li>",
"      Exclusion of renal scarring by 99mTc-dimercaptosuccinic acid (DMSA) radionuclide scan",
"     </li>",
"     <li>",
"      In cases of unilateral renal hypoplasia, compensatory hypertrophy of the contralateral kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unequivocal diagnosis is based upon histologic examination, which is rarely performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10935?source=see_link\">",
"     \"Renal hypoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal dysplasia is characterized by the presence of malformed kidney tissue elements (",
"    <a class=\"graphic graphic_picture graphicRef59147 \" href=\"UTD.htm?20/63/21491\">",
"     picture 1",
"    </a>",
"    ). Characteristic microscopic abnormalities include geographic disorganization of nephron elements, maldifferentiation of mesenchymal and epithelial elements, decreased number of nephrons, and metaplastic transformation of metanephric mesenchyme to cartilage and bone (",
"    <a class=\"graphic graphic_picture graphicRef54805 \" href=\"UTD.htm?0/35/563\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Dysplastic kidneys are variable in size but most are smaller than normal. Size is often determined by the presence or absence of cysts.",
"   </p>",
"   <p>",
"    Renal dysplasia may be unilateral or bilateral and occurs in 2 to 4 per 1000 births. The male-to-female ratio for bilateral renal dysplasia is 1.3:1 and for unilateral dysplasia is 1.9:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal dysplasia may be discovered during routine antenatal screening or postnatally when renal ultrasonography is performed in a dysmorphic infant. Bilateral dysplasia is likely to be diagnosed earlier than unilateral dysplasia especially if oligohydramnios is present. Renal ultrasound features include increased echogenicity as a result of abnormal renal parenchymal tissue, poor corticomedullary differentiation, and parenchymal cysts.",
"   </p>",
"   <p>",
"    Infants with bilateral dysplasia may have impaired renal function at birth and subsequent progressive renal failure may occur. Associated urological findings include abnormalities of the renal pelvis and calyces (congenital hydronephrosis) and ureters (duplicating collecting system), megaureter, ureteral stenosis, and vesicoureteral reflux (VUR) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/17\">",
"     17",
"    </a>",
"    ]. As a result, symptomatic presentation may occur due to complications associated with these urological anomalies including urinary tract infection, hematuria, fever, and abdominal pain.",
"   </p>",
"   <p>",
"    Because of the frequent association of renal dysplasia with a collecting system anomaly, voiding cystourethrography may be considered in all patients with renal dysplasia. If there is an associated urological abnormality such as VUR in the normal contralateral kidney, children with unilateral renal dysplasia may be at increased risk of long-term sequelae of renal scarring from recurrent urinary tract infection. DMSA radionuclide scan can provide further information on the differential function of each kidney. For example, multicystic dysplastic kidney (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Multicystic dysplasia'",
"    </a>",
"    below) typically has no viable functional renal tissue and, therefore, no detectable renal blood flow or renal function. However, there may be rare variations of segmental dysplasia. Thus, these imaging studies may be useful in defining baseline renal function and risk of future renal damage.",
"   </p>",
"   <p>",
"    The prognosis of renal dysplasia depends on whether there is unilateral versus bilateral disease. In general, the long-term outcome of unilateral renal dysplasia is excellent, particularly if there is a normal contralateral kidney. Serial ultrasonography can assess compensatory renal growth of a normal contralateral kidney and any further change in the size of the abnormal kidney.",
"   </p>",
"   <p>",
"    A more detailed description of the radiological studies used in postnatal evaluation in infants with CAKUT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Postnatal evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Multicystic dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multicystic dysplastic kidney (MCDK) is a nonfunctioning dysplastic kidney with multiple cysts, which is thought to arise from an alteration in renal parenchymal differentiation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68485 \" href=\"UTD.htm?43/34/44576\">",
"     image 1",
"    </a>",
"    ). MCDK consists of a nonreniform mass of cysts and connective tissue, and is most commonly detected by routine antenatal screening. Most infants with unilateral MCDK are asymptomatic. The clinical manifestations, management and natural course of MCDK are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal cystic diseases in children\", section on 'Multicystic dysplastic kidney'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal agenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal agenesis is defined as congenital absence of renal parenchymal tissue and results from major disruption of metanephric development at an early stage. Unilateral RA accounts for 5 percent of renal malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/11\">",
"     11",
"    </a>",
"    ]. The incidence of renal agenesis is approximately 1 per 2900 births [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/24\">",
"     24",
"    </a>",
"    ]. Males are more commonly affected than females with a male-to-female ratio of 1.7:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple factors are thought to be implicated in the pathogenesis of renal agenesis including mutations in genes important in renal development (eg, Ret or Gdnf) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/17\">",
"     17",
"    </a>",
"    ], and teratogenic and environmental agents (eg, retinoic acid and cocaine exposure) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients with unilateral renal agenesis are asymptomatic, and the diagnosis is often detected coincidentally with routine antenatal ultrasonography. Other urological abnormalities have been reported in up to 33 to 65 percent of unilateral cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], and as a result, patients present with symptoms due to associated complications of such anomalies including urinary tract infection or obstruction.",
"   </p>",
"   <p>",
"    Vesicoureteral reflux (VUR) is the most commonly identified urological abnormality, occurring in approximately 37 percent of patients with unilateral renal agenesis. The severity of VUR is reported to range from grade II to IV [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/29\">",
"     29",
"    </a>",
"    ]. Other urological anomalies include obstruction of the ureteropelvic junction (UPJ) in 6 to 7 percent, and ureterovesical junction (UVJ) in 11 to 18 percent of patients with renal agenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonrenal associated anomalies include cardiac anomalies (most commonly septal anomalies), genital tract, and gastrointestinal, respiratory, and skeletal malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Females with renal agenesis are also at risk for M&uuml;llerian abnormalities such as uterine didyphius",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vaginal duplication. These patients are part of the spectrum of Mayer-Rokitansky syndrome. They should be counseled about the possibility of M&uuml;llerian anomalies that typically present during the onset of puberty with menstrual obstruction symptoms such as cyclical pain, excessive discharge,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection.",
"   </p>",
"   <p>",
"    The contralateral normal kidney is expected to undergo compensatory hypertrophy in patients with unilateral renal agenesis. As a result, serial ultrasonography is recommended to monitor for renal compensatory growth. If compensatory hypertrophy is not observed, ongoing monitoring of the patient is recommended with yearly assessment of blood pressure and renal function by measuring serum creatinine. If there is an elevation in either blood pressure or serum creatinine, management should be focused on interventions to slow or prevent progression towards chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Slowing chronic kidney disease progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there may be an absence of renal tissue in the renal fossa, renal tissue (renal ectopy) may be found in other sites. This was illustrated in a retrospective review of 13,705 fetuses who had antenatal ultrasounds [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/30\">",
"     30",
"    </a>",
"    ]. Of the 40 cases of an empty renal fossa identified, the underlying cause was renal ectopy in 24 patients, unilateral renal agenesis in 13, horseshoe kidney in 2, and crossed fused renal ectopy in one patient. Thus, a finding of an empty renal fossa should direct the search for an ectopic kidney. The clinician may choose to perform a static renal scan with DMSA to confirm the diagnosis of renal agenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28487?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal ectopic and fusion anomalies\", section on 'Renal ectopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Static renal scan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased risk of renal impairment and hypertension has been previously reported in some but not all patients with unilateral renal agenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/31\">",
"     31",
"    </a>",
"    ]. Such complications tend to occur in obese patients as a result of glomerular hyperfiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients with a normal body mass index and a solitary functioning kidney usually have a favorable long-term outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal tubular dysgenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal tubular dysgenesis is characterized by the absence or poor development of proximal tubules and is accompanied by thickening of the renal arterial vasculature from the arcuate to the afferent arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/33\">",
"     33",
"    </a>",
"    ]. To date, there have been 63 cases of sporadic or familial cases reported.",
"   </p>",
"   <p>",
"    This disorder may be inherited or acquired.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in the genes that encode renin, angiotensinogen, angiotensin converting enzyme (ACE), and angiotensin II receptor type 1 (AT1) have all been associated with autosomal recessive renal tubular dysgenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/33\">",
"       33",
"      </a>",
"      ]. Mutations may be inherited in an autosomal recessive pattern or two different mutations affecting the same allele may result in a compound heterozygote.",
"     </li>",
"     <li>",
"      Acquired causes include twin-twin transfusion syndrome, which can occur in monochorionic twin pregnancies, and prenatal exposure to ACE inhibitors (ACEI) or angiotensin II receptor blockers (ARBs). The clinical features of affected fetuses exposed to ACEI and ARBs include early onset of oligohydramnios, detected at or before 20 weeks gestation, and result in persistent postnatal anuria with renal failure, hypocalvaria with large fontanelles, and in severe cases, Potter syndrome (oligohydramniosis, lung hypoplasia, characteristic facies of pseudoepicanthus, recessed chin, posteriorly rotated, flattened ears and flattened nose) (",
"      <a class=\"graphic graphic_picture graphicRef72847 \" href=\"UTD.htm?22/12/22721\">",
"       picture 3",
"      </a>",
"      ). Severe refractory hypotension also has been described in those infants who survive beyond the neonatal period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal ultrasonography is characteristically normal in infants with renal tubular dysgenesis. The majority of patients die in the perinatal period secondary to renal failure or lung hypoplasia. There is a single report of patients who have survived the neonatal period with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Genetic cystic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic cystic renal diseases are disorders of terminal epithelial differentiation. A brief summary of these disorders is presented here and more detailed discussions for each disorder are presented separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive polycystic kidney disease (ARPKD) &ndash; ARPKD is characterized by multiple microscopic cysts, principally involving the distal collecting ducts. It is caused by mutations in the PKHD1 gene, which codes for fibrocystin. Clinical manifestations include oligohydramnios, pulmonary hypoplasia, hypertension, congestive cardiac failure, liver disease, and renal failure. The perinatal prognosis depends on the pulmonary status. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"       \"Autosomal recessive polycystic kidney disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autosomal dominant polycystic kidney disease (ADPKD) &ndash; ADPKD is characterized by bilateral renal enlargement secondary to multiple cysts. It is caused by mutations in either PKD1 (85 percent of patients) or PKD2 genes (15 percent), which encode polycystin 1 and polycystin 2, respectively. These proteins are localized to the primary cilia of renal epithelial cells. There is a greater variability in clinical manifestations of ADPKD with most patients having significant clinical findings only in adulthood. However, there is a subset of children who have an early onset of disease (in utero or in the first year of life) with symptoms similar to those with ARPKD. These include gross or microscopic hematuria, hypertension, proteinuria, cyst infection, and renal insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"       \"Autosomal recessive polycystic kidney disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephronophthisis (NPH) &ndash; NPH, the more common form of recessive cystic kidney disease, is characterized by abnormal renal tubules, interstitial inflammation, and fibrosis. To date, several recessive mutations have been identified (NPHP1-11, NPHP1L, SDCCAG8) that encode for proteins involved with primary ciliary function, basal body function, and planar cell polarity. Clinical presentation is characterized by the insidious onset of chronic renal failure with symptoms of polyuria, polydipsia, and decreased urinary concentrating capacity. Nephronophthisis is associated with retinal degeneration in Senior Loken syndrome and with cerebellar vermis aplasia and intellectual disability (mental retardation) as well as retinal degeneration in Joubert syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link\">",
"       \"Genetics and pathogenesis of nephronophthisis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANOMALIES OF RENAL EMBRYONIC MIGRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disruption of the normal embryologic migration of the kidneys results in renal ectopia (eg, pelvic kidney) and fusion anomalies (eg, horseshoe kidney (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73581 \" href=\"UTD.htm?22/54/23393\">",
"     image 2",
"    </a>",
"    )). In general, patients with an ectopic or fused kidney(s) are asymptomatic and diagnosed coincidentally, usually by antenatal ultrasonography. In patients diagnosed symptomatically with either anomaly, symptoms at presentation are generally related to associated complications including urinary tract infection, obstruction, and renal calculi.",
"   </p>",
"   <p>",
"    Patients with renal ectopy or fused kidneys are at increased risk for other anomalies especially genitourinary abnormalities, such as vesicoureteral reflux (VUR). Renal ectopic and fusion anomalies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28487?source=see_link\">",
"     \"Renal ectopic and fusion anomalies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANOMALIES OF THE COLLECTING SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anomalies of the collecting system include abnormalities of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal pelvis (eg, ureteropelvic junction obstruction) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=see_link\">",
"       \"Congenital ureteropelvic junction obstruction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ureter (eg, megaureter, ectopic ureter, ureterocele, or vesicoureteral reflux) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1479?source=see_link\">",
"       \"Primary megaureter in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=see_link\">",
"       \"Ectopic ureter\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link\">",
"       \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41093?source=see_link\">",
"       \"Ureterocele\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bladder (eg, bladder exstrophy) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24966?source=see_link\">",
"       \"Clinical manifestations and initial management of infants with bladder exstrophy\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Urethra (eg, posterior urethral valve) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=see_link\">",
"       \"Clinical presentation and diagnosis of posterior urethral valves\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12936677\">",
"    <span class=\"h2\">",
"     Duplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete or partial duplication of the renal collecting system is the most common congenital anomaly of the urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/35\">",
"     35",
"    </a>",
"    ]. Autopsy studies report an estimated incidence of 0.8 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22472/abstract/36\">",
"     36",
"    </a>",
"    ]. Double collecting systems are thought to result from duplication of the ureteric bud with the superior bud associated with the upper renal pole and the inferior bud with the lower renal pole.",
"   </p>",
"   <p>",
"    In complete duplication, the kidney has two separate pelvicaliceal systems and two ureters. The ureter from the lower collecting system usually enters the bladder in the trigone, whereas the ureter from the upper collecting system can have a normal insertion in the trigone or be inserted ectopically in the bladder or elsewhere. In boys, insertion can occur in the posterior urethra, ejaculatory ducts, or epididymis and in girls into the vagina or uterus. Ectopic insertion of the ureter can result in obstruction or VUR. Depending upon the location of the ectopic insertion, incontinence also may be present.",
"   </p>",
"   <p>",
"    Partial duplication is more common than complete duplication. In these cases, the kidney has two separate pelvicaliceal systems with either a single ureter or two ureters that unite prior to insertion into the bladder.",
"   </p>",
"   <p>",
"    In patients with asymptomatic uncomplicated (no dilation) duplication of the collecting system, no further intervention or referral is needed. However, if there is a history of urinary tract infection or dilatation, referral to a pediatric urologist is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital anomalies of the kidney and urinary tract (CAKUT) constitute approximately 20 to 30 percent of all anomalies identified in the prenatal period.",
"     </li>",
"     <li>",
"      The reported incidence of CAKUT in live and stillborn infants is 0.3 to 1.6 per 1000. Nonrenal anomalies are seen in 30 percent of infants with CAKUT. A combination of CAKUT and non-renal anomalies are found in more than 200 described syndromes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CAKUT represent a broad range of disorders that result from abnormal embryogenic renal development due to renal parenchymal malformations, abnormalities in renal migration, or abnormalities in the developing collecting system. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Embryology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malformations of the renal parenchyma result in failure of normal nephron development as seen in renal dysplasia, renal agenesis, renal tubular dysgenesis, and polycystic renal diseases. The pathogenesis of renal parenchymal malformations is multifactorial involving genetic (",
"      <a class=\"graphic graphic_table graphicRef75351 \" href=\"UTD.htm?0/25/413\">",
"       table 2",
"      </a>",
"      ) and environmental factors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Renal parenchymal malformations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link&amp;anchor=H3#H3\">",
"       \"Renal cystic diseases in children\", section on 'Multicystic dysplastic kidney'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"       \"Autosomal recessive polycystic kidney disease in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link\">",
"       \"Genetics and pathogenesis of nephronophthisis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link\">",
"       \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disruption of the normal embryologic migration of the kidneys results in renal ectopia (eg, pelvic kidney) and fusion anomalies (eg, horseshoe kidney). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Anomalies of renal embryonic migration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28487?source=see_link\">",
"       \"Renal ectopic and fusion anomalies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormalities in the development of the collecting system result in anomalies of the renal pelvis (eg, ureteropelvic junction obstruction), ureter (eg, megaureter, ectopic ureter, or vesicoureteral reflux), bladder (eg, bladder exstrophy), and urethra (eg, posterior urethral valve). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=see_link\">",
"       \"Congenital ureteropelvic junction obstruction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1479?source=see_link\">",
"       \"Primary megaureter in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=see_link\">",
"       \"Ectopic ureter\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24966?source=see_link\">",
"       \"Clinical manifestations and initial management of infants with bladder exstrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link\">",
"       \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/1\">",
"      Queisser-Luft A, Stolz G, Wiesel A, et al. Malformations in newborn: results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990-1998). Arch Gynecol Obstet 2002; 266:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/2\">",
"      Seikaly MG, Ho PL, Emmett L, et al. Chronic renal insufficiency in children: the 2001 Annual Report of the NAPRTCS. Pediatr Nephrol 2003; 18:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/3\">",
"      Sanna-Cherchi S, Ravani P, Corbani V, et al. Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney Int 2009; 76:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/4\">",
"      Glassberg KI. Normal and abnormal development of the kidney: a clinician's interpretation of current knowledge. J Urol 2002; 167:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/5\">",
"      Jain S, Encinas M, Johnson EM Jr, Milbrandt J. Critical and distinct roles for key RET tyrosine docking sites in renal development. Genes Dev 2006; 20:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/6\">",
"      Tabatabaeifar M, Schlingmann KP, Litwin M, et al. Functional analysis of BMP4 mutations identified in pediatric CAKUT patients. Pediatr Nephrol 2009; 24:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/7\">",
"      Reidy KJ, Rosenblum ND. Cell and molecular biology of kidney development. Semin Nephrol 2009; 29:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/8\">",
"      Gribouval O, Gonzales M, Neuhaus T, et al. Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. Nat Genet 2005; 37:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/9\">",
"      Vats KR, Ishwad C, Singla I, et al. A locus for renal malformations including vesico-ureteric reflux on chromosome 13q33-34. J Am Soc Nephrol 2006; 17:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/10\">",
"      Sanna-Cherchi S, Caridi G, Weng PL, et al. Genetic approaches to human renal agenesis/hypoplasia and dysplasia. Pediatr Nephrol 2007; 22:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/11\">",
"      Wiesel A, Queisser-Luft A, Clementi M, et al. Prenatal detection of congenital renal malformations by fetal ultrasonographic examination: an analysis of 709,030 births in 12 European countries. Eur J Med Genet 2005; 48:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/12\">",
"      Livera LN, Brookfield DS, Egginton JA, Hawnaur JM. Antenatal ultrasonography to detect fetal renal abnormalities: a prospective screening programme. BMJ 1989; 298:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/13\">",
"      Caiulo VA, Caiulo S, Gargasole C, et al. Ultrasound mass screening for congenital anomalies of the kidney and urinary tract. Pediatr Nephrol 2012; 27:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/14\">",
"      Reuss A, Wladimiroff JW, Niermeijer MF. Antenatal diagnosis of renal tract anomalies by ultrasound. Pediatr Nephrol 1987; 1:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/15\">",
"      Shnorhavorian M, Bittner R, Wright JL, Schwartz SM. Maternal risk factors for congenital urinary anomalies: results of a population-based case-control study. Urology 2011; 78:1156.",
"     </a>",
"    </li>",
"    <li>",
"     Limwongse C, Cassidy SB. Syndromes and malformations of the urinary tract. In: Pediatric Nephrology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Williams &amp; Wilkins, Philadelphia 2004. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/17\">",
"      Piscione TD, Rosenblum ND. The malformed kidney: disruption of glomerular and tubular development. Clin Genet 1999; 56:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/18\">",
"      Barr M Jr, Cohen MM Jr. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Teratology 1991; 44:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/19\">",
"      Martinovic J, Benachi A, Laurent N, et al. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 2001; 358:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/20\">",
"      Batourina E, Tsai S, Lambert S, et al. Apoptosis induced by vitamin A signaling is crucial for connecting the ureters to the bladder. Nat Genet 2005; 37:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/21\">",
"      Weber S, Moriniere V, Kn&uuml;ppel T, et al. Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study. J Am Soc Nephrol 2006; 17:2864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/22\">",
"      Wilson JG, Warkany J. Malformations in the genito-urinary tract induced by maternal vitamin A deficiency in the rat. Am J Anat 1948; 83:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/23\">",
"      Harris J, Robert E, K&auml;ll&eacute;n B. Epidemiologic characteristics of kidney malformations. Eur J Epidemiol 2000; 16:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/24\">",
"      Parikh CR, McCall D, Engelman C, Schrier RW. Congenital renal agenesis: case-control analysis of birth characteristics. Am J Kidney Dis 2002; 39:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/25\">",
"      Shenefelt RE. Morphogenesis of malformations in hamsters caused by retinoic acid: relation to dose and stage at treatment. Teratology 1972; 5:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/26\">",
"      Ch&aacute;vez GF, Mulinare J, Cordero JF. Maternal cocaine use during early pregnancy as a risk factor for congenital urogenital anomalies. JAMA 1989; 262:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/27\">",
"      Kaneyama K, Yamataka A, Satake S, et al. Associated urologic anomalies in children with solitary kidney. J Pediatr Surg 2004; 39:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/28\">",
"      Krzemie�� G, Roszkowska-Blaim M, Kostro I, et al. Urological anomalies in children with renal agenesis or multicystic dysplastic kidney. J Appl Genet 2006; 47:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/29\">",
"      Song JT, Ritchey ML, Zerin JM, Bloom DA. Incidence of vesicoureteral reflux in children with unilateral renal agenesis. J Urol 1995; 153:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/30\">",
"      Yuksel A, Batukan C. Sonographic findings of fetuses with an empty renal fossa and normal amniotic fluid volume. Fetal Diagn Ther 2004; 19:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/31\">",
"      Argueso LR, Ritchey ML, Boyle ET Jr, et al. Prognosis of patients with unilateral renal agenesis. Pediatr Nephrol 1992; 6:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/32\">",
"      Gonz&aacute;lez E, Guti&eacute;rrez E, Morales E, et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int 2005; 68:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/33\">",
"      Lacoste M, Cai Y, Guicharnaud L, et al. Renal tubular dysgenesis, a not uncommon autosomal recessive disorder leading to oligohydramnios: Role of the Renin-Angiotensin system. J Am Soc Nephrol 2006; 17:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/34\">",
"      Zingg-Schenk A, Bacchetta J, Corvol P, et al. Inherited renal tubular dysgenesis: the first patients surviving the neonatal period. Eur J Pediatr 2008; 167:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/35\">",
"      Williams H. Renal revision: from lobulation to duplication--what is normal? Arch Dis Child Educ Pract Ed 2007; 92:ep152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22472/abstract/36\">",
"      Decter RM. Renal duplication and fusion anomalies. Pediatr Clin North Am 1997; 44:1323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6110 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22472=[""].join("\n");
var outline_f21_60_22472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RENAL PARENCHYMAL MALFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Multicystic dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal tubular dysgenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Genetic cystic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANOMALIES OF RENAL EMBRYONIC MIGRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANOMALIES OF THE COLLECTING SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12936677\">",
"      Duplication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6110\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6110|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/34/44576\" title=\"diagnostic image 1\">",
"      US and intraop MCDK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/54/23393\" title=\"diagnostic image 2\">",
"      CT scan horseshoe kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6110|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/41/12948\" title=\"figure 1\">",
"      Kidney embryology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6110|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/63/21491\" title=\"picture 1\">",
"      Multicystic dysplastic kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/35/563\" title=\"picture 2\">",
"      Dysplastic kidney pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/12/22721\" title=\"picture 3\">",
"      Potters syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6110|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/40/17037\" title=\"table 1\">",
"      Gene defects renal malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/25/413\" title=\"table 2\">",
"      Prevalence renal anomalies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24966?source=related_link\">",
"      Clinical manifestations and initial management of infants with bladder exstrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=related_link\">",
"      Clinical presentation and diagnosis of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=related_link\">",
"      Congenital ureteropelvic junction obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=related_link\">",
"      Ectopic ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=related_link\">",
"      Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1479?source=related_link\">",
"      Primary megaureter in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=related_link\">",
"      Renal cystic diseases in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28487?source=related_link\">",
"      Renal ectopic and fusion anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10935?source=related_link\">",
"      Renal hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41093?source=related_link\">",
"      Ureterocele",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_60_22473="Uterine leiomyoma (fibroid) embolization";
var content_f21_60_22473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uterine leiomyoma (fibroid) embolization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22473/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22473/contributors\">",
"     Ducksoo Kim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22473/contributors\">",
"     Stephen D Baer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22473/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22473/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22473/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22473/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/60/22473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine fibroid embolization (UFE) is a nonsurgical treatment option for premenopausal women with bothersome fibroid-related symptoms who wish to retain their uterus, escape side effects associated with prolonged medical therapy, and avoid surgery (eg, myomectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The procedure is based upon the hypothesis that bilateral reduction of uterine arterial blood flow will result in infarction of fibroids and control bothersome fibroid-related symptoms, while sparing normal myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine fibroid embolization (UFE) is indicated for relief of bothersome bulk-related symptoms and abnormal uterine bleeding due to fibroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The procedure is rarely indicated in postmenopausal women since fibroids naturally regress after menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/4\">",
"     4",
"    </a>",
"    ]. Other relative contraindications to UFE include: current use of gonadotropin releasing hormone (GnRH) agonists, submucosal fibroids, extensive adenomyosis, previous internal iliac artery ligation, and plans for future pregnancy. Many of these relative contraindications are subjective, based on the judgment and experience of the clinician (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Pregnancy after UFE'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Ovarian dysfunction'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Large fibroids do not appear to be a contraindication to UFE. As an example, a series of 71 women with a large fibroid burden (dominant fibroid of &gt;10 cm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a uterine volume of &gt;700 cm) who underwent UFE had no serious complications after an average of 48 months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/5\">",
"     5",
"    </a>",
"    ]. However, some studies have found extremely large fibroids (&gt;24 weeks uterine gestation size or multiple fibroids larger than 10 cm in diameter) to be a relative contraindication because of serious complications such as severe abdominal pain, infection, sepsis, and ischemic uterine injury requiring emergent hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myomectomy is generally the preferred approach to pedunculated tumors since they do not respond well to UFE, and procedure-related complications (necrosis, separation, torsion) are more common than after UFE of intramural fibroids. However, some data suggest that UFE can be performed successfully in women with pedunculated fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hysteroscopic resection is the optimal approach to managing submucosal tumors. Women with extensive uterine adenomyomatosis also may be better served by a surgical approach (hysterectomy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GnRH agonists are a relative contraindication because they decrease uterine artery caliber and uterine artery blood flow. The decrease in caliber makes it more difficult to catheterize the uterine artery, while the decrease in blood flow limits the deposition of plastic beads into the target fibroid.",
"   </p>",
"   <p>",
"    Absolute contraindications include pregnancy, active genitourinary infection, malignancy, significant immunosuppression, severe vascular disease limiting access, and high risk of complications from contrast media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetricians has recommended UFE as a safe and effective option for women who wish to retain their uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALTERNATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroids can also be treated medically or surgically (hysterectomy, myomectomy). A detailed discussion of the various options for treatment of fibroids can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREPROCEDURE ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reasonable effort to ensure an accurate diagnosis is important before uterine fibroid embolization (UFE), since symptoms attributable to fibroids may be due to other pathology. One concern is that there may be a delay in diagnosis of malignancy (eg, ovarian or endometrial cancer, uterine sarcoma) since no tissue is obtained for confirmation of the diagnosis. We ensure that the patient has had an endometrial biopsy and recent pap smear to screen for uterine malignancy prior to the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy should be excluded, including the possibility of luteal phase pregnancy. This can be ascertained by performing the procedure in the early follicular phase or anytime in patients using a reliable form of contraception.",
"   </p>",
"   <p>",
"    We also test for bacteriuria and sexually transmitted infection in patients at risk and obtain a baseline complete blood count, BUN, creatinine, and prothrombin",
"    <span class=\"nowrap\">",
"     time/international",
"    </span>",
"    normalized ratio (INR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) has become the standard imaging tool in women planning UFE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Most women with symptoms or physical examination findings suggestive of uterine fibroids undergo pelvic ultrasonography for confirmation of the presence of myomas. However, ultrasonography does not perform as well as MRI in determining fibroid characteristics. Another benefit of MRI is superior detection of adenomyosis, which may interfere with UFE efficacy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications and contraindications'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link&amp;anchor=H7#H7\">",
"     \"Uterine adenomyosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI allows the differentiation of fibroids from other pelvic tumors and is superior to ultrasound in the imaging of fibroids because it can provide improved spatial and contrast resolution, along with freedom from the effects of acoustic shadowing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibroid size, number, and location are three potential predictors of successful UFE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. As an example, UFE in women with submucosal or pedunculated subserosal fibroids is associated with an increased risk of complications. Information provided by MRI regarding these fibroid characteristics may affect clinical decision making. A retrospective study of 49 women who underwent evaluation for UFE with both sonography and MRI reported that the correlation between the two imaging modalities for identification of the largest fibroid was high (correlation coefficient 0.87), but was low for fibroid location (0.17); discrepancies were also noted in the number of fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/14\">",
"     14",
"    </a>",
"    ]. MRI results showing a difference in fibroid size or location from that seen on ultrasound resulted in a change in management in 11 patients (22 percent), UFE was cancelled in four patients and was performed in another seven patients thought to be poor candidates based upon sonography results. A limitation of this study is that clinical outcomes were not reported.",
"   </p>",
"   <p>",
"    Tissue viability within a fibroid is another factor that is useful in pre-UFE decision-making [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/15,21\">",
"     15,21",
"    </a>",
"    ]. This can be determined using contrast-enhanced MRI, but not sonography. &nbsp;",
"   </p>",
"   <p>",
"    Further study is needed to confirm the role of MRI for evaluation of women prior to UFE.",
"   </p>",
"   <p>",
"    In addition, in patient follow-up after embolization, contrast-enhanced MRI can be used to predict any regrowth of uninfarcted fibroid tissue and to select patients for repeat embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/15,22,23\">",
"     15,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patient preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an intrauterine contraceptive device (IUD) is in place, it has been traditionally recommended to remove it because it can be a risk factor for postprocedural infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/12\">",
"     12",
"    </a>",
"    ]. However, a small retrospective study involving 20 women with an IUD who underwent UFE and had no infectious complication after a mean follow-up of 20.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/24\">",
"     24",
"    </a>",
"    ] suggests that the presence of an IUD might not be considered a contraindication for UFE. Nevertheless, in our practice, we remove IUDs when clinically feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general description of the procedure for embolization of pelvic arteries is described in detail separately; a summary of uterine artery embolization is provided below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=see_link&amp;anchor=H2#H2\">",
"     \"Interventional radiology in management of gynecological disorders\", section on 'Transcatheter embolization procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The procedure is performed under local anesthesia. The most common approach to percutaneous embolization is via the right or left femoral artery. Initially, an arteriogram is performed to visualize the pelvic vasculature, especially identification of the uterine artery, its origin, and any anatomic variations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/25\">",
"     25",
"    </a>",
"    ]. It is also important to note whether any branches of the ovarian artery are supplying the fibroids, and the size of these branches, as they are a potential cause of treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/26\">",
"     26",
"    </a>",
"    ]. When feasible, in our practice, we attempt to embolize any significant uteroovarian connections by means of superselective catheterization to avoid non-target embolization of the ovaries. Each patient is counseled prior to the procedure and presented with a decision tree, should the above situation arise. Sometimes, the patient with significant ovarian contribution must weigh the prospect of ovarian embolization with possible premature ovarian failure versus incomplete embolization resulting in unsatisfactory clinical outcome.",
"   </p>",
"   <p>",
"    For uterine fibroid embolization (UFE), a catheter is passed into the distal portion of one of the uterine arteries under fluoroscopic guidance, followed by infusion of the embolizing agent (",
"    <a class=\"graphic graphic_figure graphicRef62884 graphicRef74642 \" href=\"UTD.htm?34/16/35074\">",
"     figure 1A-B",
"    </a>",
"    ). The infusion is continued until flow to the fibroids ceases, but slight antegrade flow is still present in the uterine artery. The procedure is then repeated on the other uterine artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63412 graphicRef77132 graphicRef56265 graphicRef70070 \" href=\"UTD.htm?19/10/19626\">",
"     image 1A-D",
"    </a>",
"    ). Unilateral UFE is associated with a significantly higher risk of failure (ie, need for subsequent hysterectomy or repeat UFE procedures) than bilateral UFE (39 versus 18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral embolization results in ischemic necrosis and hyaline and calcific degeneration of the fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Technical failure is rare (&lt;1 percent) and is generally due to very difficult uterine artery anatomy or dominant blood supply to fibroids from ovarian arteries.",
"   </p>",
"   <p>",
"    The average procedure time is about an hour [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POSTPROCEDURE ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;After uterine fibroid embolization (UFE), we see the patient at two weeks, three months, six months, and then yearly to monitor her for bulk-related symptoms and abnormal uterine bleeding. We perform imaging studies if clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all women experience postprocedure pain, which is believed to be due to ischemia of the fibroids and uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/31\">",
"     31",
"    </a>",
"    ]. The degree of pain ranges from mild to severe cramping. Options for pain control depend on the severity and include patient-controlled analgesia, oral or parenteral opiates, and nonsteroidal anti-inflammatory drugs. In our experience, the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    to use of epidural anesthesia does not seem justified. Epidural anesthesia is effective, but carries additional risks, such as possible spinal headache, and increase in the cost of the procedure. We have found that intravenous conscious sedation during the procedure followed by PCA (patient controlled anesthesia) suffices for postprocedural pain management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Vaginal discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women experience a bloody discharge that typically lasts two weeks, but may persist for months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/12\">",
"     12",
"    </a>",
"    ]. While discharge of short duration is common, prolonged discharge is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Postembolization syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the procedure, most women experience postembolization syndrome, which consists of pelvic pain and cramping, nausea, vomiting, fever, fatigue, myalgias, malaise, and leukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/12\">",
"     12",
"    </a>",
"    ]. These symptoms occur within the first 48 hours of the procedure and gradually improve over seven days. Patients who do not gradually improve should be evaluated for other conditions, such as sepsis.",
"   </p>",
"   <p>",
"    Although UFE can be performed as an outpatient procedure, most services admit patients for management of postembolization symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/32\">",
"     32",
"    </a>",
"    ]. Patient-controlled analgesia, oral or parenteral opiates, nonsteroidal anti-inflammatory drugs, antipyretics, and antiemetics can be started preemptively in the recovery room. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications are rare, but are more likely when there is a single large leiomyoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/7,33,34\">",
"     7,33,34",
"    </a>",
"    ]. There have been two case reports of fatal septic complications associated with UFE procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/7,35\">",
"     7,35",
"    </a>",
"    ]. In addition, a fatal nontarget embolization resulted from an intrafibroid arteriovenous fistula in conjunction with presence of a patent foramen ovale [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/36\">",
"     36",
"    </a>",
"    ]. Venous thromboembolic complications have been reported occurring at an estimated rate of 0.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/37\">",
"     37",
"    </a>",
"    ] and are usually not fatal. However, there has been one case report of a fatal pulmonary embolus occurring after UFE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/38\">",
"     38",
"    </a>",
"    ]. Nevertheless, mortality does not appear to be higher than that associated with hysterectomy for treatment of leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type and rate of other reported complications depend, in part, on whether criteria used were from the Society of Interventional Radiology (SIR) or the American College of Obstetricians and Gynecologists (ACOG) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/30,40\">",
"     30,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the most common complications follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever (2 to 4 percent)",
"     </li>",
"     <li>",
"      Vaginal passage of a leiomyoma (2.5 to 5 percent).",
"     </li>",
"     <li>",
"      Readmission (2.4 to 3.5 percent)",
"     </li>",
"     <li>",
"      Need for unplanned surgical procedure (1 to 2.5 percent)",
"     </li>",
"     <li>",
"      Allergic",
"      <span class=\"nowrap\">",
"       reaction/rash",
"      </span>",
"      (2.5 percent)",
"     </li>",
"     <li>",
"      Hemorrhage (0.15 to 0.75 percent)",
"     </li>",
"     <li>",
"      Life-threatening event (0.2 to 0.5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Submucosal myomas may become endocavitary after UFE and be expelled vaginally [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/41\">",
"     41",
"    </a>",
"    ]. One study reported that this was most likely to occur with submucosal fibroids that were less than 66 ml in volume [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/42\">",
"     42",
"    </a>",
"    ]. In another study, the authors assessed the ratio between the largest endometrial interface and the maximum dimension of the dominant submucosal fibroid (interface dimension ratio) before and after UFE using contrast-enhanced pelvic magnetic resonance imaging (MRI) in 49 women over a two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/43\">",
"     43",
"    </a>",
"    ]. They found that submucosal fibroids with an interface-dimension ratio of greater than 0.55 are more likely to migrate into the endometrial cavity after UFE. The majority of these are expelled spontaneously without significant symptoms. Rarely, submucosal fibroids greater than 6 cm in size that become endocavitary may cause postprocedural complications requiring further intervention and medical treatment. It should be noted that passage of leiomyoma tissue can occur up to a year following UFE and thus does not follow the expected time course of surgical complications. Small fibroids undergo autolysis and often present clinically by passage of tissue fragments with or without discharge. Symptoms are minimal. Larger fibroids may present with significant",
"    <span class=\"nowrap\">",
"     cramping/labor-type",
"    </span>",
"    pains since dilatation of the cervix is needed to pass the large volume of tissue. Large fibroids may pass spontaneously, or require an intervention.",
"   </p>",
"   <p>",
"    Febrile morbidity may be related to endomyometritis",
"    <span class=\"nowrap\">",
"     with/without",
"    </span>",
"    pyometra, salpingitis, tuboovarian abscess, infected fibroids, or infection at the groin insertion site [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/12\">",
"     12",
"    </a>",
"    ]. Antibiotic therapy may be effective, but if the infection does not respond, surgical drainage (eg, dilatation and curettage)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resection or hysterectomy is necessary.",
"   </p>",
"   <p>",
"    In addition, there have been case reports of femoral nerve injury, pulmonary embolism, bilateral iliac artery thrombosis, ischemic infarction of the uterus, labial necrosis, focal bladder necrosis, vesicouterine fistula, and development of uterine wall defects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/7,30,35,40,44-47\">",
"     7,30,35,40,44-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Undetected sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since preoperative evaluation (including endometrial biopsy and MR imaging) cannot distinguish between benign leiomyomas and myometrial neoplasms of low or high grade malignancy (eg, leiomyosarcoma) with certainty, a misdiagnosed sarcoma may be treated by UFE rather than surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. However, this risk is very small, given the rarity of these tumors. A literature review noted only six cases of uterine sarcoma in women who had undergone UFE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/50\">",
"     50",
"    </a>",
"    ]. Because the risk of leiomyosarcoma increases with age, UFE is not recommended for menopausal women with new onset or worsening symptoms related to presumed leiomyomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ovarian dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some, but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], studies have reported loss of ovarian function after UFE, manifested as transient or permanent amenorrhea, possibly from nontarget (unintentional) embolization into ovarian arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. This complication appears to be age related. Instances of premature menopause have been reported in 2 to 3 percent of patients under the age of 45, and in approximately 8 percent of women over the age of 45 following UFE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/6,8,53,55-58\">",
"     6,8,53,55-58",
"    </a>",
"    ]. Three-year follow-up data from the UFE registry found that 1.6 percent of women under 40 who underwent UFE were amenorrheic within three years, although whether these patients' periods stopped independently of the UFE was not determined [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, one case report described amenorrhea following UFE that was secondary to endometrial atrophy despite normal ovarian function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few well-designed studies that compare rates of ovarian dysfunction after UFE against the complication rates of myomectomy or hysterectomy in similar patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/61\">",
"     61",
"    </a>",
"    ]. In general, the fertility rate after UFE appears to be similar to that achieved by myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/61\">",
"     61",
"    </a>",
"    ]. In one randomized trial, anti-mullerian hormone showed diminished ovarian reserve at 24 months following treatment for both women undergoing hysterectomy and UFE, with a trend toward greater impairment in the UFE group [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/62\">",
"     62",
"    </a>",
"    ]. Likewise, in follow-up from a randomized controlled trial, reproductive outcomes at two years were better following surgery than UFE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women desiring future fertility, more studies need to be done before UFE can be recommended as the first-line approach for women with fibroids who wish to preserve future fertility. However, for those women who wish to preserve fertility, but are unsuitable candidates for surgery, UFE offers an option to treat their fibroid symptoms while also possibly preserving fertility. Patients who desire fertility need to be fully counseled as to the current data available regarding pregnancies after UFE (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Pregnancy after UFE'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    For women desiring future fertility, studies examining subtle forms of impairment of ovarian function that may lead to subfertility need to be done before UFE can be recommended as the first-line approach for women with fibroids who wish to preserve future fertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Short-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term outcomes have generally been favorable when the procedure was performed by experienced interventional radiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/4\">",
"     4",
"    </a>",
"    ]. Data compiled from several large series show [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/6,9,30,64-68\">",
"     6,9,30,64-68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The procedure could be completed in 98 to 100 percent of patients",
"     </li>",
"     <li>",
"      Improvement of abnormal bleeding occurred in 85 to 94 percent of women",
"     </li>",
"     <li>",
"      Improvement of dysmenorrhea occurred in 77 to 79 percent",
"     </li>",
"     <li>",
"      Bulk-related symptoms were controlled in 60 to 96 percent",
"     </li>",
"     <li>",
"      Mean uterine volume was reduced by 35 to 60 percent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81418 graphicRef55027 \" href=\"UTD.htm?41/50/42791\">",
"       image 2A-B",
"      </a>",
"      ). Submucosal location is a strong predictor of volume reduction since these myomas are often expelled; mean reduction in uterine volume is lower in women with only intramural or subserosal myomas [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/57,69-72\">",
"       57,69-72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Society of Interventional Radiology maintains a prospective uterine fibroid embolization (UFE) registry involving more than 3000 women. Follow-up data on 1278 patients three years after UFE are available; this series is the largest that has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      95 percent of patients had significant improvement in symptoms and quality of life",
"     </li>",
"     <li>",
"      29 percent developed post-procedure amenorrhea; 21 percent of amenorrheic patients were 45 years of age or younger",
"     </li>",
"     <li>",
"      14.4 percent underwent an additional invasive procedure: hysterectomy (9.8 percent), myomectomy (2.8 percent), repeat UFE (1.8 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Series with follow-up over five or more years report higher rates of secondary intervention. Although approximately 75 percent of patients reported uterine bleeding was normal or improved five or more years after UFE, approximately 20 percent reported having undergone a second procedure (hysterectomy, myomectomy, repeat UFE) to control fibroid-related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/27,73-75\">",
"     27,73-75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Data from comparative studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few comparative studies have been performed; representative examples are illustrated below [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/76-81\">",
"     76-81",
"    </a>",
"    ]. In general, patients report high rates of symptom control and satisfaction after UFE, hysterectomy, and myomectomy. UFE has the shortest period of recovery. All of the procedures have similar rates of complications, although the complications are different for the various procedures. Approximately 20 percent of women who undergo UFE will undergo a subsequent procedure (reembolization, hysterectomy, or myomectomy) because of persistent symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Systematic review",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of 54 study populations including 8159 women who underwent UFE found that the rate of major complications was 2.9 percent and the rate of readmission after the procedure was 2.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/82\">",
"     82",
"    </a>",
"    ]. The rate of hysterectomy for resolution of a complication of UFE was 0.7 percent. The rate of reintervention (repeat UFE, myomectomy, or hysterectomy) per patient-year was 5.3 percent with follow-up ranging from 0.25 to 5 years.",
"   </p>",
"   <p>",
"    Another systematic review of",
"    <strong>",
"     UFE versus hysterectomy",
"    </strong>",
"    found that UFE took less time (weighted mean difference -16 minutes, 95% CI -26 to -7 minutes), had less blood loss (weighted mean difference -405 mLs, 95% CI -512 to -298 mLs), a shorter duration of hospitalization (weighted mean difference -3.3 days, 95% CI -3.8 to -2.8 days), and faster resumption to normal activities (weighted mean difference -27 days, 95% CI -36 to -17 days), but more unscheduled visits after discharge (OR 1.8, 95% CI 0.98-3.30) and a higher rate of readmission within 42 days (OR 6.0, 95% CI 1.1-31.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/83\">",
"     83",
"    </a>",
"    ]. Both groups were satisfied with their treatment.",
"   </p>",
"   <p>",
"    The same systematic review identified only one randomized trial (n = 121) comparing",
"    <strong>",
"     UFE versus open or laparoscopic myomectomy,",
"    </strong>",
"    which showed that UFE had significant decreases in operative duration (an average of 34 minutes shorter), hospital stay (an average of 1.6 days less), and time to return to normal daily activity (an average of 16 days less) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/79,83\">",
"     79,83",
"    </a>",
"    ]. Of note, this trial combined the data for open and laparoscopic myomectomy, making it difficult to apply these findings regarding operative duration and recovery time. Few serious perioperative complications occurred for either procedure (UFE: 3 of 30; myomectomy: 1 of 33). The rate of improvement in symptoms at six-months postoperatively was similar for both UFE and myomectomy (88 and 93 percent). However, after an average of 17 months, the rate of reintervention was significantly higher for UFE (37 versus 6 percent). Further randomized trials comparing UFE with open or laparoscopic myomectomy or hysterectomy are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     REST trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Randomized Trial of Embolization versus Surgical Treatment for Fibroids (REST trial) trial compared the outcome of UFE versus surgery in women with symptomatic fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/84\">",
"     84",
"    </a>",
"    ]. In this trial, 106 women were assigned to UFE and 51 women were assigned to surgical therapy; women in the latter group decided whether the surgical intervention would be hysterectomy (43 women) or myomectomy (8 women).",
"   </p>",
"   <p>",
"    Compared to surgical therapy, UFE was associated with significantly shorter duration of hospitalization (1 versus 5 days) and time until return to work (20 versus 62 days). The overall frequency of adverse events was similar for both groups; however, adverse events were more likely to occur during hospitalization in women who underwent surgery versus after discharge in women who underwent UFE.",
"   </p>",
"   <p>",
"    Twenty-one women in the UFE group subsequently underwent reembolization or hysterectomy due to treatment failure; 10 of these procedures were in the first year after UFE. In the surgery group, one myomectomy was converted to a hysterectomy intraoperatively. Quality of life scores were similar for both groups at 12 months follow-up. Although 20 percent of women treated with UFE ultimately underwent a second procedure, initial treatment was successful in most women and enabled a more rapid return to usual activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     EMMY trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EMbolization with hysterectoMY (EMMY) trial randomly assigned 177 women with symptomatic",
"    <span class=\"nowrap\">",
"     fibroids/menorrhagia",
"    </span>",
"    who were eligible for hysterectomy to uterine fibroid embolization (UFE) or hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/76,77,85\">",
"     76,77,85",
"    </a>",
"    ]. In the short-term, the rate of major complications was not significantly different for the two procedures (less than 5 percent). UFE was associated with more minor complications and readmissions, but shorter hospital stay and shorter duration to resumption of usual activities. UFE procedural failures were mainly due to difficult anatomy and absence of a uterine artery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At five-year follow-up, 28 percent of UFE patients had subsequently undergone hysterectomy; health-related quality of life measures improved and were similar in both treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pregnancy after UFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of pregnancy after UFE has not been established; therefore, the procedure is usually reserved for women who are not contemplating future childbearing. A systematic review and several case series of pregnancies following UFE have reported adverse outcomes in some pregnancies following UAE, including miscarriage, preterm delivery, placental problems, and malpresentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/61,63,87-92\">",
"     61,63,87-92",
"    </a>",
"    ]. Some of the increased risk of adverse pregnancy outcome could be explained by confounders, such as a higher prevalence of advanced maternal age and infertility in the women who underwent UFE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     REPEAT PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat uterine fibroid embolization (UFE) can be performed, but data on these procedures are limited. In one series, 24 women underwent repeat embolization for recurrent or persistent symptoms 6 to 66 months post UFE and 90 percent had successful symptom control after the second procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22473/abstract/93\">",
"     93",
"    </a>",
"    ]. MR imaging before repeat embolization revealed incomplete infarction of tumors present before the first embolization in",
"    <span class=\"nowrap\">",
"     22/24",
"    </span>",
"    patients and new tumors in",
"    <span class=\"nowrap\">",
"     12/24",
"    </span>",
"    patients",
"    <span class=\"nowrap\">",
"     (2/12",
"    </span>",
"    had new tumors only). During repeat UFE, nine patients required ovarian artery embolization to occlude ovarian supply to the uterus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/21/2386?source=see_link\">",
"       \"Patient information: Uterine artery embolization (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uterine fibroid embolization (UFE) reduces uterine arterial blood flow, which results in infarction of fibroids and reduction in fibroid-related symptoms. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      UFE is indicated for relief of bothersome bulk-related symptoms and abnormal uterine bleeding due to fibroids in premenopausal women. We suggest avoiding this procedure in premenopausal women with large pedunculated or submucosal fibroids (&gt;6 cm), extensive adenomyosis, an extremely large fibroid uterus (&gt;24 weeks of pregnancy in uterus size or multiple fibroids larger than 10 cm in diameter), or plans for future pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). UFE should also be avoided in postmenopausal women. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest magnetic resonance imaging (MRI) with and without contrast medium before UFE. MRI is useful for excluding large pedunculated fibroids and other disease processes that might be better treated by another modality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Preprocedure issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest bilateral uterine artery embolization as unilateral procedures are associated with a significantly higher risk of failure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common side effects and complications of UFE are pain, postembolization syndrome, fever, allergic reaction, vaginal passage of a leiomyoma, readmission, and need for an unplanned procedure. Misdiagnosis of a leiomyosarcoma and postoperative ovarian dysfunction are additional serious concerns. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Postprocedure issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Five or more years after UFE, approximately 75 percent of patients report uterine bleeding is normal or improved, approximately 20 percent report having undergone a second procedure (hysterectomy, myomectomy, repeat UFE) to control fibroid-related symptoms. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The safety of pregnancy after UFE has not been established; therefore, the procedure is usually reserved for women who are not contemplating future childbearing. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Pregnancy after UFE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/1\">",
"      McLucas B, Goodwin S, Adler L, et al. Pregnancy following uterine fibroid embolization. Int J Gynaecol Obstet 2001; 74:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/2\">",
"      Goldberg J, Pereira L, Berghella V. Pregnancy after uterine artery embolization. Obstet Gynecol 2002; 100:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/3\">",
"      Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial embolisation to treat uterine myomata. Lancet 1995; 346:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/4\">",
"      Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Uterine artery embolization. Obstet Gynecol 2004; 103:403.",
"     </a>",
"    </li>",
"    <li>",
"     Smeets, AJ, Nijenhuis, RJ, van Rooij, WJ, et al. Uterine artery embolization in patients with a large fibroid burden: long-term clinical and MR follow-up. Cardiovasc Intervent Radiol 2010; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/6\">",
"      Spies JB, Ascher SA, Roth AR, et al. Uterine artery embolization for leiomyomata. Obstet Gynecol 2001; 98:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/7\">",
"      Vashisht A, Studd J, Carey A, Burn P. Fatal septicaemia after fibroid embolisation. Lancet 1999; 354:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/8\">",
"      Pelage JP, Le Dref O, Soyer P, et al. Fibroid-related menorrhagia: treatment with superselective embolization of the uterine arteries and midterm follow-up. Radiology 2000; 215:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/9\">",
"      Worthington-Kirsch RL, Popky GL, Hutchins FL Jr. Uterine arterial embolization for the management of leiomyomas: quality-of-life assessment and clinical response. Radiology 1998; 208:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/10\">",
"      Goodwin SC, McLucas B, Lee M, et al. Uterine artery embolization for the treatment of uterine leiomyomata midterm results. J Vasc Interv Radiol 1999; 10:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/11\">",
"      Smeets AJ, Nijenhuis RJ, Boekkooi PF, et al. Safety and effectiveness of uterine artery embolization in patients with pedunculated fibroids. J Vasc Interv Radiol 2009; 20:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/12\">",
"      Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. Uterine fibroid embolization (UFE). Number 150, October 2004. Int J Gynaecol Obstet 2005; 89:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/13\">",
"      American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol 2008; 112:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/14\">",
"      Spielmann AL, Keogh C, Forster BB, et al. Comparison of MRI and sonography in the preliminary evaluation for fibroid embolization. AJR Am J Roentgenol 2006; 187:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/15\">",
"      Keeling, AN, Reidy, JF. Imaging and treatment of uterine fibroids, including the role of uterine artery embolization. Imaging 2007; 19:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/16\">",
"      Dudiak CM, Turner DA, Patel SK, et al. Uterine leiomyomas in the infertile patient: preoperative localization with MR imaging versus US and hysterosalpingography. Radiology 1988; 167:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/17\">",
"      Zawin M, McCarthy S, Scoutt LM, Comite F. High-field MRI and US evaluation of the pelvis in women with leiomyomas. Magn Reson Imaging 1990; 8:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/18\">",
"      Spies JB, Roth AR, Jha RC, et al. Leiomyomata treated with uterine artery embolization: factors associated with successful symptom and imaging outcome. Radiology 2002; 222:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/19\">",
"      Pelage JP, Walker WJ, Le Dref O, et al. Treatment of uterine fibroids. Lancet 2001; 357:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/20\">",
"      Katsumori T, Nakajima K, Mihara T. Is a large fibroid a high-risk factor for uterine artery embolization? AJR Am J Roentgenol 2003; 181:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/21\">",
"      Nikolaidis P, Siddiqi AJ, Carr JC, et al. Incidence of nonviable leiomyomas on contrast material-enhanced pelvic MR imaging in patients referred for uterine artery embolization. J Vasc Interv Radiol 2005; 16:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/22\">",
"      Pelage JP, Guaou NG, Jha RC, et al. Uterine fibroid tumors: long-term MR imaging outcome after embolization. Radiology 2004; 230:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/23\">",
"      Chrisman HB, West D, Corpuz B, et al. Primary failure of uterine artery embolization: use of magnetic resonance imaging to select patients for repeated embolization. J Vasc Interv Radiol 2005; 16:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/24\">",
"      Smeets AJ, Nijenhuis RJ, Boekkooi PF, et al. Is an intrauterine device a contraindication for uterine artery embolization? A study of 20 patients. J Vasc Interv Radiol 2010; 21:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/25\">",
"      Worthington-Kirsch RL, Andrews RT, Siskin GP, et al. II. Uterine fibroid embolization: technical aspects. Tech Vasc Interv Radiol 2002; 5:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/26\">",
"      Abbara S, Nikolic B, Pelage JP, et al. Frequency and extent of uterine perfusion via ovarian arteries observed during uterine artery embolization for leiomyomas. AJR Am J Roentgenol 2007; 188:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/27\">",
"      Gabriel-Cox K, Jacobson GF, Armstrong MA, et al. Predictors of hysterectomy after uterine artery embolization for leiomyoma. Am J Obstet Gynecol 2007; 196:588.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/28\">",
"      Worthington-Kirsch RL, Siskin GP. Uterine artery embolization for symptomatic myomata. J Intensive Care Med 2004; 19:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/29\">",
"      Siskin GP, Eaton LA Jr, Stainken BF, et al. Pathologic findings in a uterine leiomyoma after bilateral uterine artery embolization. J Vasc Interv Radiol 1999; 10:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/30\">",
"      Worthington-Kirsch R, Spies JB, Myers ER, et al. The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: short-term outcomes. Obstet Gynecol 2005; 106:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/31\">",
"      Burbank F, Hutchins FL Jr. Uterine Artery Occlusion by Embolization or Surgery for the Treatment of Fibroids: A Unifying Hypothesis-Transient Uterine Ischemia. J Am Assoc Gynecol Laparosc 2000; 7:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/32\">",
"      Siskin GP, Stainken BF, Dowling K, et al. Outpatient uterine artery embolization for symptomatic uterine fibroids: experience in 49 patients. J Vasc Interv Radiol 2000; 11:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/33\">",
"      Goodwin SC, Walker WJ. Uterine artery embolization for the treatment of uterine fibroids. Curr Opin Obstet Gynecol 1998; 10:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/34\">",
"      Payne JF, Haney AF. Serious complications of uterine artery embolization for conservative treatment of fibroids. Fertil Steril 2003; 79:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/35\">",
"      de Blok S, de Vries C, Prinssen HM, et al. Fatal sepsis after uterine artery embolization with microspheres. J Vasc Interv Radiol 2003; 14:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/36\">",
"      Fatal nontarget embolization via an intrafibroid arterial venous fistula during uterine fibroid embolization. J Vasc Interv Radiol 2009; 20:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/37\">",
"      Czeyda-Pommersheim F, Magee ST, Cooper C, et al. Venous thromboembolism after uterine fibroid embolization. Cardiovasc Intervent Radiol 2006; 29:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/38\">",
"      Hamoda H, Tait P, Edmonds DK. Fatal pulmonary embolus after uterine artery fibroid embolisation. Cardiovasc Intervent Radiol 2009; 32:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/39\">",
"      Parker WH. Uterine myomas: management. Fertil Steril 2007; 88:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/40\">",
"      Spies JB, Spector A, Roth AR, et al. Complications after uterine artery embolization for leiomyomas. Obstet Gynecol 2002; 100:873.",
"     </a>",
"    </li>",
"    <li>",
"     Verma, SK. Submucosal fibroids becoming endocavitary following uterine artery embolization: risk assessment by MRI.",
"    </li>",
"    <li>",
"     Radeleff, B, Eiers, M, Bellemann, N, Ramsauer, S, et al. Expulsion of dominant submucosal fibroids after uterine artery embolization. Eur J Radiol 2009; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/43\">",
"      van der Kooij SM, Klint E, Hehenkamp WJ, et al. Implementation of uterine artery embolisation for symptomatic uterine fibroids: an inventory. Neth J Med 2011; 69:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/44\">",
"      Godfrey CD, Zbella EA. Uterine necrosis after uterine artery embolization for leiomyoma. Obstet Gynecol 2001; 98:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/45\">",
"      Yeagley TJ, Goldberg J, Klein TA, Bonn J. Labial necrosis after uterine artery embolization for leiomyomata. Obstet Gynecol 2002; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/46\">",
"      Sterling KM, Vogelzang RL, Chrisman HB, et al. V. Uterine fibroid embolization: management of complications. Tech Vasc Interv Radiol 2002; 5:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/47\">",
"      El-Miligy M, Gordon A, Houston G. Focal myometrial defect and partial placenta accreta in a pregnancy following bilateral uterine artery embolization. J Vasc Interv Radiol 2007; 18:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/48\">",
"      D'Angelo A, Amso NN, Wood A. Uterine leiomyosarcoma discovered after uterine artery embolisation. J Obstet Gynaecol 2003; 23:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/49\">",
"      Al-Badr A, Faught W. Uterine artery embolization in an undiagnosed uterine sarcoma. Obstet Gynecol 2001; 97:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/50\">",
"      Joyce A, Hessami S, Heller D. Leiomyosarcoma after uterine artery embolization. A case report. J Reprod Med 2001; 46:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/51\">",
"      Tropeano G, Di Stasi C, Litwicka K, et al. Uterine artery embolization for fibroids does not have adverse effects on ovarian reserve in regularly cycling women younger than 40 years. Fertil Steril 2004; 81:1055.",
"     </a>",
"    </li>",
"    <li>",
"     Tropeano, G, Di Stasi, C, Amoroso, S, Gualano, MR, Bonomo, L, et al. Long-term effects of uterine fibroid embolization on ovarian reserve: a prospective cohort study. Fertil Steril 2010; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/53\">",
"      Chrisman HB, Saker MB, Ryu RK, et al. The impact of uterine fibroid embolization on resumption of menses and ovarian function. J Vasc Interv Radiol 2000; 11:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/54\">",
"      Tulandi T, Sammour A, Valenti D, et al. Ovarian reserve after uterine artery embolization for leiomyomata. Fertil Steril 2002; 78:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/55\">",
"      Spies JB, Roth AR, Gonsalves SM, Murphy-Skrzyniarz KM. Ovarian function after uterine artery embolization for leiomyomata: assessment with use of serum follicle stimulating hormone assay. J Vasc Interv Radiol 2001; 12:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/56\">",
"      Bradley LD. Uterine fibroid embolization: a viable alternative to hysterectomy. Am J Obstet Gynecol 2009; 201:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/57\">",
"      Hutchins FL Jr, Worthington-Kirsch R, Berkowitz RP. Selective uterine artery embolization as primary treatment for symptomatic leiomyomata uteri. J Am Assoc Gynecol Laparosc 1999; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/58\">",
"      Hurst BS, Stackhouse DJ, Matthews ML, Marshburn PB. Uterine artery embolization for symptomatic uterine myomas. Fertil Steril 2000; 74:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/59\">",
"      Goodwin SC, Spies JB, Worthington-Kirsch R, et al. Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol 2008; 111:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/60\">",
"      Tropeano G, Litwicka K, Di Stasi C, et al. Permanent amenorrhea associated with endometrial atrophy after uterine artery embolization for symptomatic uterine fibroids. Fertil Steril 2003; 79:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/61\">",
"      Goldberg J, Pereira L, Berghella V, et al. Pregnancy outcomes after treatment for fibromyomata: uterine artery embolization versus laparoscopic myomectomy. Am J Obstet Gynecol 2004; 191:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/62\">",
"      Hehenkamp WJ, Volkers NA, Broekmans FJ, et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007; 22:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/63\">",
"      Mara M, Maskova J, Fucikova Z, et al. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008; 31:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/64\">",
"      Pron G, Bennett J, Common A, et al. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril 2003; 79:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/65\">",
"      Walker WJ, Pelage JP. Uterine artery embolisation for symptomatic fibroids: clinical results in 400 women with imaging follow up. BJOG 2002; 109:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/66\">",
"      Watson GM, Walker WJ. Uterine artery embolisation for the treatment of symptomatic fibroids in 114 women: reduction in size of the fibroids and women's views of the success of the treatment. BJOG 2002; 109:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/67\">",
"      Kim, D, Baer, SD. Uterine artery embolization for abnormal bleeding. OBG Management 2005; 17:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/68\">",
"      Rajan DK, Beecroft JR, Clark TW, et al. Risk of intrauterine infectious complications after uterine artery embolization. J Vasc Interv Radiol 2004; 15:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/69\">",
"      Jha RC, Ascher SM, Imaoka I, Spies JB. Symptomatic fibroleiomyomata: MR imaging of the uterus before and after uterine arterial embolization. Radiology 2000; 217:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/70\">",
"      Abbara S, Spies JB, Scialli AR, et al. Transcervical expulsion of a fibroid as a result of uterine artery embolization for leiomyomata. J Vasc Interv Radiol 1999; 10:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/71\">",
"      Berkowitz RP, Hutchins FL Jr, Worthington-Kirsch RL. Vaginal expulsion of submucosal fibroids after uterine artery embolization. A report of three cases. J Reprod Med 1999; 44:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/72\">",
"      Naguib NN, Mbalisike E, Nour-Eldin NE, et al. Leiomyoma volume changes at follow-up after uterine artery embolization: correlation with the initial leiomyoma volume and location. J Vasc Interv Radiol 2010; 21:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/73\">",
"      Walker WJ, Barton-Smith P. Long-term follow up of uterine artery embolisation--an effective alternative in the treatment of fibroids. BJOG 2006; 113:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/74\">",
"      Spies JB, Bruno J, Czeyda-Pommersheim F, et al. Long-term outcome of uterine artery embolization of leiomyomata. Obstet Gynecol 2005; 106:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/75\">",
"      Popovic M, Berzaczy D, Puchner S, et al. Long-term quality of life assessment among patients undergoing uterine fibroid embolization. AJR Am J Roentgenol 2009; 193:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/76\">",
"      Hehenkamp WJ, Volkers NA, Donderwinkel PF, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids (EMMY trial): peri- and postprocedural results from a randomized controlled trial. Am J Obstet Gynecol 2005; 193:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/77\">",
"      Volkers NA, Hehenkamp WJ, Birnie E, et al. Uterine artery embolization in the treatment of symptomatic uterine fibroid tumors (EMMY trial): periprocedural results and complications. J Vasc Interv Radiol 2006; 17:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/78\">",
"      Spies JB, Cooper JM, Worthington-Kirsch R, et al. Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multicenter study. Am J Obstet Gynecol 2004; 191:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/79\">",
"      Mara M, Fucikova Z, Maskova J, et al. Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2006; 126:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/80\">",
"      Goodwin SC, Bradley LD, Lipman JC, et al. Uterine artery embolization versus myomectomy: a multicenter comparative study. Fertil Steril 2006; 85:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/81\">",
"      Siskin GP, Shlansky-Goldberg RD, Goodwin SC, et al. A prospective multicenter comparative study between myomectomy and uterine artery embolization with polyvinyl alcohol microspheres: long-term clinical outcomes in patients with symptomatic uterine fibroids. J Vasc Interv Radiol 2006; 17:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/82\">",
"      Toor SS, Jaberi A, Macdonald DB, et al. Complication rates and effectiveness of uterine artery embolization in the treatment of symptomatic leiomyomas: a systematic review and meta-analysis. AJR Am J Roentgenol 2012; 199:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/83\">",
"      Gupta JK, Sinha AS, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev 2006; :CD005073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/84\">",
"      Edwards RD, Moss JG, Lumsden MA, et al. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 2007; 356:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/85\">",
"      Volkers NA, Hehenkamp WJ, Birnie E, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years' outcome from the randomized EMMY trial. Am J Obstet Gynecol 2007; 196:519.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/86\">",
"      van der Kooij SM, Hehenkamp WJ, Volkers NA, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 5-year outcome from the randomized EMMY trial. Am J Obstet Gynecol 2010; 203:105.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/87\">",
"      Pron G, Mocarski E, Bennett J, et al. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol 2005; 105:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/88\">",
"      Carpenter TT, Walker WJ. Pregnancy following uterine artery embolisation for symptomatic fibroids: a series of 26 completed pregnancies. BJOG 2005; 112:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/89\">",
"      Walker WJ, McDowell SJ. Pregnancy after uterine artery embolization for leiomyomata: a series of 56 completed pregnancies. Am J Obstet Gynecol 2006; 195:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/90\">",
"      Pinto Pab&oacute;n I, Magret JP, Unzurrunzaga EA, et al. Pregnancy after uterine fibroid embolization: follow-up of 100 patients embolized using tris-acryl gelatin microspheres. Fertil Steril 2008; 90:2356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/91\">",
"      Ravina JH, Vigneron NC, Aymard A, et al. Pregnancy after embolization of uterine myoma: report of 12 cases. Fertil Steril 2000; 73:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/92\">",
"      Homer H, Saridogan E. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril 2010; 94:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22473/abstract/93\">",
"      Yousefi S, Czeyda-Pommersheim F, White AM, et al. Repeat uterine artery embolization: indications and technical findings. J Vasc Interv Radiol 2006; 17:1923.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3299 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22473=[""].join("\n");
var outline_f21_60_22473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALTERNATIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREPROCEDURE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patient preparation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POSTPROCEDURE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Vaginal discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Postembolization syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Undetected sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ovarian dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Short-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Data from comparative studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Systematic review",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - REST trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - EMMY trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pregnancy after UFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      REPEAT PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3299|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/17/7443\" title=\"diagnostic image 1A\">",
"      Fibroid embolization 4b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/12/11456\" title=\"diagnostic image 1B\">",
"      Fibroid embolization 4c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/39/27250\" title=\"diagnostic image 1C\">",
"      Fibroid embolization 4d",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/36/17984\" title=\"diagnostic image 1D\">",
"      Fibroid embolization 4e",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/47/3827\" title=\"diagnostic image 2A\">",
"      Fibroid embolization 5a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/14/21730\" title=\"diagnostic image 2B\">",
"      Fibroid embolization 5b",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3299|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/45/23263\" title=\"figure 1A\">",
"      Fibroid embolization 2a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/62/12271\" title=\"figure 1B\">",
"      Fibroid embolization 2b",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/21/2386?source=related_link\">",
"      Patient information: Uterine artery embolization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_60_22474="Approach to the child with occult toxic exposure";
var content_f21_60_22474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with occult toxic exposure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22474/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22474/contributors\">",
"     Larissa I Velez, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22474/contributors\">",
"     J Greene Shepherd, PharmD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22474/contributors\">",
"     Collin S Goto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22474/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22474/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/60/22474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/60/22474/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/60/22474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, in 2002, there were approximately 2.4 million toxic exposures reported to the American Association of Poison Control Centers Toxic Exposure Surveillance System (AAPCC-TESS) by 64 participating poison centers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/1\">",
"     1",
"    </a>",
"    ]. The true annual incidence of such exposures is unknown because of under-diagnosis and underreporting, but it was estimated to be 4.6 million. Two-thirds of these exposures occurred in children younger than 20 years of age, one-half in children younger than six years, and almost one-quarter in children younger than two years. Every physician who cares for children should be familiar with the evaluation and management of poisoning.",
"   </p>",
"   <p>",
"    The general approach and initial management of the child who is suspected to have ingested or inhaled an unknown poison is reviewed here. Specific issues relating to management of common drug overdoses are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of occult ingestion varies depending upon the ingested substance and can range from asymptomatic to critically ill. Occult toxic exposure should be considered in the differential diagnosis of children who present with acute onset of multiorgan system dysfunction, altered mental status, respiratory or cardiac compromise, unexplained metabolic acidosis, seizures, or a puzzling clinical picture [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The index of suspicion should be raised if the child is in the \"at risk\" age group (one to four years of age)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    has a previous history of ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intentional etiologies for occult poisonings, including suicide attempts in older children and adolescents, and child abuse via forced ingestion in young children, particularly those who are younger than one year of age, must not be overlooked [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the poisoned child begins with initial evaluation and stabilization followed by a thorough evaluation to identify the agent(s) involved and assess the severity of exposure. The possibility of concomitant trauma or illness must be recognized and addressed before initiation of decontamination [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tempo, sequence, methods, and priorities of management are dictated by the toxin(s) involved, the presenting and predicted severity of poisoning, and the presenting phase of poisoning. Management usually begins with stabilization of the airway, breathing, and circulation, and treatment of life-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limb-threatening trauma. It is then directed to the provision of supportive care, prevention of poison absorption, and when appropriate, administration of antidotes and enhancement of elimination [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AND STABILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid evaluation of mental status, vital signs, and pupils enables classification of the patient into a state of physiologic excitation (eg, central nervous system stimulation and increased temperature, pulse, blood pressure, and respiration); depression (depressed mental status and decreased temperature, pulse, blood pressure, and respiration); or mixed physiologic state. This initial characterization helps to direct initial stabilization efforts and provides a clue to the etiologic agent (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The airway of patients who have ingested an unknown substance must be monitored carefully. The patency of the airway and gag reflex should be evaluated in patients who are sedated or obtunded. Even those who are awake and talking must be monitored closely because their condition can deteriorate quickly. The position of the head should be optimized to maintain airway patency. Endotracheal intubation should be performed in all patients in whom the airway is threatened. If intubation is necessary, cervical spine stabilization must be maintained if trauma is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the airway is adequately secured, the quality of breathing must be evaluated. Poisoned patients may develop respiratory failure for many reasons. Some toxins decrease the respiratory drive, whereas others impair muscle contraction; still other toxins may directly damage the lung parenchyma or result in pulmonary edema. Any of these mechanisms may result in hypoxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercapnia (",
"    <a class=\"graphic graphic_table graphicRef69772 \" href=\"UTD.htm?42/43/43708\">",
"     table 2",
"    </a>",
"    ). In a symptomatic or rapidly deteriorating patient, measurement of arterial blood gas should be obtained. Supplemental oxygenation should be provided to maintain oxygen saturation &gt;95 percent. Intubation and ventilation are required in patients who cannot sustain adequate oxygenation or ventilation or who have severe acid-base disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intoxication by various drugs may cause blood pressure and heart rate abnormalities (",
"    <a class=\"graphic graphic_table graphicRef51200 \" href=\"UTD.htm?29/8/29838\">",
"     table 3",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac conduction disturbances ranging from minor QT changes to a wide QRS complex form (",
"    <a class=\"graphic graphic_table graphicRef66773 \" href=\"UTD.htm?23/11/23742\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Blood pressure measurement and a 12-lead electrocardiogram (ECG) should be obtained in all patients who present with occult toxic exposure. Continuous cardiac monitoring is often necessary.",
"   </p>",
"   <p>",
"    The evaluation and management of circulatory compromise in patients with intoxication of unknown or multiple agents should occur according to Advanced Cardiac Life Support (ACLS) or Pediatric Advanced Life Support (PALS) guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=see_link\">",
"     \"Assessment of perfusion in pediatric resuscitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link\">",
"     \"Primary drugs in pediatric resuscitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The child should be evaluated for signs of shock, and because of the potential for rapid decompensation, at least one intravenous (IV) line should be established in the stable patient and two large bore lines in the unstable or deteriorating patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link\">",
"     \"Physiology and classification of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Altered mental status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various drugs can cause mental status changes ranging from agitation to coma (",
"    <a class=\"graphic graphic_table graphicRef80618 \" href=\"UTD.htm?3/52/3918\">",
"     table 5",
"    </a>",
"    ). Hypoxemia and hypoglycemia are two common causes of altered mental status in the poisoned patient that should be promptly evaluated and addressed during initial stabilization. In addition, administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"     naloxone",
"    </a>",
"    or thiamine should be considered in poisoned children and adolescents who are thought to have opiate intoxication or thiamine deficiency, respectively. In contrast, the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/58/38821?source=see_link\">",
"     flumazenil",
"    </a>",
"    to reverse benzodiazepine ingestion is not routinely recommended because of potential serious adverse effects (eg, precipitation of seizures) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hypoxemia",
"      </strong>",
"      &ndash; Rapid evaluation of oxygenation should be performed in all patients with altered mental status. This can be performed with a bedside pulse oximeter",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arterial blood gas measurement, which provides additional information about the patient's ventilation and acid-base status and may, in turn, affect diagnosis and management. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Ancillary studies'",
"      </a>",
"      below.) Pulse oximetry does not reflect oxyhemoglobin saturation in patients with carbon monoxide poisoning. If carbon monoxide toxicity is a diagnostic consideration, the carboxyhemoglobin level should be measured by cooximetry using a blood gas sample. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"       \"Carbon monoxide poisoning\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Humidified oxygen should be administered to symptomatic poisoned children with altered mental status. Endotracheal intubation is required in patients who cannot sustain adequate ventilation or oxygenation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypoglycemia",
"      </strong>",
"      &ndash; Several drugs cause hypoglycemia (",
"      <a class=\"graphic graphic_table graphicRef73635 \" href=\"UTD.htm?40/37/41564\">",
"       table 6",
"      </a>",
"      ); rapid assessment of blood glucose can be performed at the bedside with a glucose strip [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/12\">",
"       12",
"      </a>",
"      ]. A concentrated dextrose solution should be administered if blood glucose is low, the accuracy of the result is questioned, or rapid assessment of blood glucose is not available [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/2,12\">",
"       2,12",
"      </a>",
"      ]. The dose for dextrose is 0.25",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      administered intravenously or intraosseously. This is usually achieved with 2.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 10 percent dextrose solution since extravasation of higher concentrations of glucose will lead to severe tissue damage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H13#H13\">",
"       \"Approach to hypoglycemia in infants and children\", section on 'Glucose therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Opiate intoxication",
"      </strong>",
"      &ndash; Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"       naloxone",
"      </a>",
"      is indicated in patients who have depressed mental status, diminished respirations, miotic pupils, or other circumstantial evidence of opiate intoxication [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/11,14,15\">",
"       11,14,15",
"      </a>",
"      ]. The dose of naloxone varies depending upon the age of the child and the clinical scenario. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=see_link&amp;anchor=H27#H27\">",
"       \"Opioid intoxication in children and adolescents\", section on 'Naloxone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Thiamine deficiency",
"      </strong>",
"      &ndash; The administration of thiamine should be considered in children and adolescents who may be thiamine-deficient because of chronic disease, malnutrition, eating disorders, or alcoholism [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/2,12\">",
"       2,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link\">",
"       \"Wernicke's encephalopathy\"",
"      </a>",
"      .) The notion that thiamine must be given before dextrose to avoid precipitating Wernicke's encephalopathy is largely unsupported [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/12\">",
"       12",
"      </a>",
"      ]. Uptake of thiamine into cells is slower than that of dextrose [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/16\">",
"       16",
"      </a>",
"      ], and withholding dextrose until the administration of thiamine is complete may prove detrimental to those with actual hypoglycemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional considerations in the initial stabilization of the child with an unknown toxic exposure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Occult trauma",
"      </strong>",
"      &ndash; The patient should be completely undressed and examined to look for signs of occult trauma.",
"     </li>",
"     <li>",
"      <strong>",
"       Decontamination",
"      </strong>",
"      &ndash; Gastrointestinal decontamination may be indicated as part of the initial stabilization in children who have ingested a potentially life-threatening amount of poison (eg, iron) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/3\">",
"       3",
"      </a>",
"      ]. Ocular",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dermal decontamination may be necessary if coincident exposure occurred. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link\">",
"       \"Decontamination of poisoned children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF POISONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial evaluation and stabilization, efforts should be focused on identification of agent(s) involved, assessment of severity, and prediction of toxicity.",
"   </p>",
"   <p>",
"    It is essential to identify potentially fatal agents and those with delayed clinical toxicity (",
"    <a class=\"graphic graphic_table graphicRef55219 \" href=\"UTD.htm?8/2/8237\">",
"     table 7",
"    </a>",
"    ) as soon as possible so that appropriate intervention can be undertaken. The most common fatal drug ingestions in children younger than six years of age include prenatal iron supplements, antidepressants, cardiotoxic agents, and salicylates (",
"    <a class=\"graphic graphic_table graphicRef61883 \" href=\"UTD.htm?4/18/4395\">",
"     table 8",
"    </a>",
"    ). In addition, a number of drugs can be fatal if ingested by a toddler, even in small amounts (",
"    <a class=\"graphic graphic_table graphicRef76803 \" href=\"UTD.htm?15/1/15389\">",
"     table 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. The most common fatal nondrug ingestions in children younger than six years of age include hydrocarbons, alcohols, cosmetics, cleaning products, and pesticides [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/2,21,22\">",
"     2,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27736?source=see_link\">",
"     \"Hydrocarbon poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtaining an accurate history in an intoxicated patient is challenging, but crucial. The patient may be unwilling or unable to provide the details of the history [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/23\">",
"     23",
"    </a>",
"    ], and the personnel accompanying the patient to medical care may not know the details of exposure (eg, agent, time, volume, immediate clinical effects). The patient's history should be confirmed and correlated whenever possible with the signs, symptoms, and laboratory data expected from poisoning with the agent(s) implicated by history.",
"   </p>",
"   <p>",
"    In the young child, the circumstances surrounding the ingestion can provide useful information (eg, location, activity just before ingestion) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. Potential agents ingested in the kitchen, for example, may be different than those in the bathroom [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to ask about exposure to the most commonly ingested agents in children younger than six years, which include cosmetics and personal care products, cleaning products, analgesics, cough and cold preparations, topical agents, plants, pesticides, and vitamins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/1,22\">",
"     1,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to ask about recent illnesses and regular therapy with common medications. The overdosing of common medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) may result in chronic poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/2\">",
"     2",
"    </a>",
"    ]. Among the 26 fatal toxic exposures in children younger than six years of age in the United States in 2001, eight were caused by therapeutic errors (acetaminophen,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/23/39287?source=see_link\">",
"     oxycodone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Information that is provided by an adolescent patient, particularly one with an intentional ingestion, may not be reliable [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ]. Adolescents commonly present with ethanol or illicit drug intoxications. It is important to ask other household members about all medications (prescription and over-the-counter), vitamin and mineral supplements (particularly prenatal vitamins), herbal remedies, and folk remedies that are present in the home, as well as those that are used by recent visitors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/11\">",
"     11",
"    </a>",
"    ]. Adolescents may also be exposed to occult toxins in the work or school environment (eg, alkaline corrosives, gases and fumes, cleaning agents, bleaches, various drugs, acids, and hydrocarbons) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paramedics can provide important information about open containers, empty bottles, spilled contents, drug paraphernalia, or suicide notes at the scene. If such items exist, the paramedics (or someone at the scene) should bring them to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/11\">",
"     11",
"    </a>",
"    ]. Unknown pills or chemicals may be identified by consultation with a regional poison control center (1-800-222-1222), computerized poison identification system, or product manufacturer (eg, material data safety sheet).",
"   </p>",
"   <p>",
"    It is also important to know about interventions in the prehospital setting (eg, administration of oxygen, intravenous fluid, dextrose, or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"     naloxone",
"    </a>",
"    ) since these may alter the patient's condition at the time of presentation.",
"   </p>",
"   <p>",
"    Information about the quantity and timing of ingestion is helpful in making decisions about decontamination or the use of antidotes (see below). Younger children tend to ingest small quantities of single agents. In one study of 66 children (age 1.5 to 4.5 years), the volume of a \"mouthful\" was calculated by subtracting the volume of apple juice remaining in a cup after the child had taken one sip from the original volume [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/28\">",
"     28",
"    </a>",
"    ]. The mean volume of a mouthful was 9.3 mL (95% CI, 8-11 mL), with a range of 3.5 to 29 mL. In contrast to younger children, older children and adolescents, in whom the ingestion is more likely intentional, ingest larger quantities of multiple agents. In some cases, the only information that is available about the time of ingestion is the last time that the patient was observed to be doing well.",
"   </p>",
"   <p>",
"    Information from the past medical history is useful in the identification of available medications, possible coingestants, baseline health status, and potential complicating factors (eg, G6PD deficiency). If the patient or family member cannot provide this information, it may be obtained from medical records, pharmacy profiles, or Medic-Alert bracelets.",
"   </p>",
"   <p>",
"    Information from the social history may be useful in determining the circumstances, intent,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    agent of exposure. Unwitnessed, unintentional ingestions in young children tend to occur at times of decreased parental supervision (eg, when there are household visitors or holiday parties) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A history of illicit drug use in the patient or family members may provide a clue to the agent. Drug use in close family members has been associated with unintentional (unsupervised) ingestion of illicit substances [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Drug use in older siblings may encourage similar behavior in younger ones (eg, inhalant abuse). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=see_link\">",
"     \"Inhalant abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination, particularly the evaluation of mental status and vital signs, should be repeated frequently to determine the course of poisoning and the need for further intervention.",
"   </p>",
"   <p>",
"    After the initial diagnostic evaluation and stabilization, other physical findings should be sought to further define a particular toxic syndrome (toxidrome), to narrow the potential etiologies of poisoning (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"     table 1",
"    </a>",
"    ), and to evaluate the possibility of child abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    .) The diagnosis may be assisted by [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temperature alterations (",
"      <a class=\"graphic graphic_table graphicRef55439 \" href=\"UTD.htm?32/12/32973\">",
"       table 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Blood pressure and heart rate alterations (",
"      <a class=\"graphic graphic_table graphicRef51200 \" href=\"UTD.htm?29/8/29838\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Respiratory disturbances (",
"      <a class=\"graphic graphic_table graphicRef64012 \" href=\"UTD.htm?34/56/35725\">",
"       table 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pupillary findings (",
"      <a class=\"graphic graphic_table graphicRef61723 \" href=\"UTD.htm?3/59/4030\">",
"       table 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Skin findings (",
"      <a class=\"graphic graphic_table graphicRef74778 \" href=\"UTD.htm?28/51/29501\">",
"       table 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neuromuscular abnormalities (",
"      <a class=\"graphic graphic_table graphicRef64472 \" href=\"UTD.htm?27/59/28606\">",
"       table 14",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mental status alterations (",
"      <a class=\"graphic graphic_table graphicRef80618 \" href=\"UTD.htm?3/52/3918\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Characteristic odors (",
"      <a class=\"graphic graphic_table graphicRef76045 \" href=\"UTD.htm?15/17/15643\">",
"       table 15",
"      </a>",
"      ); these odors may not be detectable by all examiners",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other aspects of the physical examination may suggest particular agents or routes of exposure. Nosebleed may occur in individuals who inhale cocaine or volatile substances. The latter may also cause facial rash, flushing, blisters, or a ring of paint around the mouth and nose (the \"huffer rash\"). Wood's light (ultraviolet) examination of the patient's mouth or clothes may reveal fluorescence if the patient has ingested antifreeze solution (eg, ethylene glycol), which commonly contains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    dye (added to help in the identification of radiator leaks) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/31\">",
"     31",
"    </a>",
"    ]. Needle tracks suggest intravenous drug use.",
"   </p>",
"   <p>",
"    Discrepancies between the physical examination and the history may reflect an inaccurate ingestion history, a brief or prolonged time interval between exposure and physical examination, or intentional poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of the child with an unknown ingestion is performed to detect metabolic effects of the poison that have both diagnostic and therapeutic implications. The laboratory evaluation should include the following (",
"    <a class=\"graphic graphic_table graphicRef73635 \" href=\"UTD.htm?40/37/41564\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53698 \" href=\"UTD.htm?19/8/19598\">",
"     table 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57992 \" href=\"UTD.htm?42/40/43659\">",
"     table 17",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58822 \" href=\"UTD.htm?24/3/24637\">",
"     table 18",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid determination of blood glucose",
"     </li>",
"     <li>",
"      Acid base status",
"     </li>",
"     <li>",
"      Electrolytes",
"     </li>",
"     <li>",
"      Blood urea nitrogen and creatinine",
"     </li>",
"     <li>",
"      Serum osmolality (suspected ingestion of toxic alcohols or presence of anion gap acidosis)",
"     </li>",
"     <li>",
"      Aspartate aminotransferase (AST) and Alanine aminotransferase (if",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ingestion suspected)",
"     </li>",
"     <li>",
"      Quantitative",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      serum concentration (suicidal intent or if suspected based on history)",
"     </li>",
"     <li>",
"      Quantitative salicylate serum concentration (patients with respiratory alkalosis or metabolic acidosis)",
"     </li>",
"     <li>",
"      Urine dipstick test",
"     </li>",
"     <li>",
"      Urine pregnancy test (postmenarchal females)",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chocolate-colored blood that fails to turn pink after 10 minutes of exposure to air suggests methemoglobinemia, which may be caused by a number of agents, including aniline dyes, benzocaine-containing teething products,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/31/34288?source=see_link\">",
"     dapsone",
"    </a>",
"    , naphthalene, nitrites, and pyridium (",
"    <a class=\"graphic graphic_table graphicRef53698 \" href=\"UTD.htm?19/8/19598\">",
"     table 16",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It may be helpful to save samples of blood (10 mL, heparinized), urine (100 mL, first voided), vomitus, and gastric contents (first lavage aspiration) for subsequent analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/4\">",
"     4",
"    </a>",
"    ]. Such samples should be appropriately labeled; they should be processed and stored according to specific instructions supplied by the laboratory. Care should be taken to establish a chain of evidence for law enforcement purposes if intentional poisoning or Munchausen by proxy are suspected (this includes proper sealing, labeling, and storing of specimens to ensure that they cannot be tampered with). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Blood gas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial or venous blood gas measurement offers a rapid evaluation of acid-base status (",
"    <a class=\"graphic graphic_table graphicRef57992 \" href=\"UTD.htm?42/40/43659\">",
"     table 17",
"    </a>",
"    ), as well as assessment of oxygenation (arterial blood gas only) and ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In a symptomatic or rapidly deteriorating patient, the results of the arterial blood gas can be used to direct stabilization and supportive care while awaiting other laboratory results. Cooximetry can be used to rapidly establish the diagnosis of carbon monoxide toxicity or methemoglobinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum electrolytes provides information about renal function, which is essential for the elimination of some toxins, and further information about acid-base status (",
"    <a class=\"graphic graphic_table graphicRef73635 \" href=\"UTD.htm?40/37/41564\">",
"     table 6",
"    </a>",
"    ). The electrolyte results can be used to calculate the anion gap (Na &ndash; [Cl + HCO3]) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], which helps to differentiate among the forms of metabolic acidosis (",
"    <a class=\"graphic graphic_table graphicRef58822 \" href=\"UTD.htm?24/3/24637\">",
"     table 18",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=see_link\">",
"     \"Approach to the child with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Serum osmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum osmolality (which must be calculated by freezing point depression) is essential for the calculation of the osmolal gap. The osmolal gap is elevated in the presence of unmeasured osmotically active substances (",
"    <a class=\"graphic graphic_table graphicRef62390 \" href=\"UTD.htm?6/52/6988\">",
"     table 19",
"    </a>",
"    ). The most important substances in the group are the toxic alcohols [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Calculation of the osmolal gap requires simultaneous measurement of plasma osmolality, electrolytes, blood urea nitrogen (BUN), and creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link\">",
"     \"Serum osmolal gap\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinalysis is necessary for evaluation of rhabdomyolysis, the prompt treatment of which may prevent renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the urine can also be helpful in the diagnosis of ethylene glycol ingestion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microscopic examination of the urine may reveal calcium oxalate crystals (",
"      <a class=\"graphic graphic_picture graphicRef67694 graphicRef65169 \" href=\"UTD.htm?16/28/16836\">",
"       picture 1A-B",
"      </a>",
"      ), although the absence of crystalluria does not preclude the presence of ethylene glycol ingestion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urine examination by Wood's light (ultraviolet) may reveal fluorescence if the patient has ingested antifreeze solution, which commonly contains",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      dye (added to help in the identification of radiator leaks) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/31\">",
"       31",
"      </a>",
"      ]. However, this finding is neither sensitive nor specific for the diagnosis of ethylene glycol poisoning [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. A negative control urine sample should be tested simultaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7707604\">",
"    <span class=\"h3\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes on electrocardiogram suggest poisoning by certain agents (",
"    <a class=\"graphic graphic_table graphicRef66773 \" href=\"UTD.htm?23/11/23742\">",
"     table 4",
"    </a>",
"    ) and may indicate the need for specific intervention (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    infusion (1",
"    <span class=\"nowrap\">",
"     mEq/L))",
"    </span>",
"    for a widened QRS interval or ventricular arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Toxicology screens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for toxicology screening in patients with occult toxic exposure depends upon the clinical scenario. Toxicology screening is rarely necessary in children who have an unintentional ingestion and are asymptomatic or have clinical findings that are consistent with the history. It is indicated in children in whom the diagnosis of poisoning is uncertain, who have coma of unknown etiology, where there is suspicion of child abuse or Munchausen syndrome by proxy, and in whom the administration of an antidote depends upon the rapid identification of the toxic agent. Care should be taken to establish a chain of evidence for law enforcement purposes if intentional poisoning or Munchausen by proxy are suspected (this includes proper sealing, labeling, and storing of specimens to ensure that they cannot be tampered with). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine screens provide qualitative data about the recent use of substances included in the screen. Urine screens usually test for a limited number of substances (typically drugs of abuse). Positive and negative immunoassay screens for drugs do not absolutely confirm or refute poisoning diagnoses and may need confirmation by gas chromatography-mass spectrophotometry (GC-MS). False positives may occur if structurally similar substances cross-react with the assay (",
"    <a class=\"graphic graphic_table graphicRef58181 \" href=\"UTD.htm?24/57/25499\">",
"     table 20",
"    </a>",
"    ). On the other hand, a negative screen may reflect a drug concentration below the threshold limit of detection because the specimen was obtained before or after peak concentration.",
"   </p>",
"   <p>",
"    Qualitative screens are inexpensive and provide rapid results (usually within one hour). However, they provide no information about timing or quantity of ingestion. The information obtained rarely affects clinical management, but may be useful in anticipating withdrawal and determining psychiatric disposition [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/10,44\">",
"     10,44",
"    </a>",
"    ]. The spectrum of drugs included in the urine screen varies by institution; clinicians should be familiar with the spectrum of drugs tested at their institution [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum testing provides quantitative data and is important in the diagnosis and management of ingestion of several drugs and medications (",
"    <a class=\"graphic graphic_table graphicRef77841 \" href=\"UTD.htm?3/10/3244\">",
"     table 21",
"    </a>",
"    ). As a general rule, drug concentrations should be ordered selectively depending upon the history, physical examination findings, and clinical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/10,46\">",
"     10,46",
"    </a>",
"    ]. However, screening for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and salicylates is strongly recommended for patients with an uncertain history or intentional poisoning; few early signs may be present following lethal doses of these agents, and specific treatments are available and highly effective if implemented early [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Quantitative testing may also be considered for agents that have delayed clinical effects (",
"    <a class=\"graphic graphic_table graphicRef55219 \" href=\"UTD.htm?8/2/8237\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The interpretation of a single drug concentration for any drug must be made with caution because poisoning is a dynamic and rapidly changing process. Intervention may be required despite serum concentrations in the therapeutic range. Results of these tests should be considered in conjunction with the time of exposure. Levels that are obtained early in the course, while the drug is still distributing throughout the body, are difficult to interpret properly. On the other hand, levels drawn very late after an exposure may be deceivingly low.",
"   </p>",
"   <p>",
"    Comprehensive qualitative toxic screening of urine, blood, or other body fluids is expensive and usually requires six hours for results. Such testing rarely leads to changes in patient management and disposition, and is unlikely to affect patient outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. In one retrospective study of comprehensive toxicology screens in 463 children younger than 19 years of age, 51 percent were positive for exogenous toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/50\">",
"     50",
"    </a>",
"    ]. Among the positive screens, 97 percent were either suspected by history or physical examination, present in the limited portion of the toxicology screen, or clinically insignificant; in the remaining 3 percent, patient management was not altered as a result of the positive screen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, such a comprehensive panel may be useful in patients who are critically ill or in whom the clinical picture does not fit the stated history [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/2,23\">",
"     2,23",
"    </a>",
"    ]. The spectrum of drugs included in the comprehensive drug screen varies by institution; clinicians should be familiar with the spectrum of drugs tested at their institution [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs and toxins that can cause coma or hypotension and are not detected by most drug screens include bromides, carbon monoxide,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    , cyanide, organophosphates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34064?source=see_link\">",
"     tetrahydrozoline",
"    </a>",
"    (in over-the-counter eye drops), beta blockers, calcium-channel blockers,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/50/14118?source=see_link\">",
"     colchicine",
"    </a>",
"    , digitalis, and iron [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/2,45\">",
"     2,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Radiologic evaluation",
"    </span>",
"   </p>",
"   <p>",
"    Plain radiographs of the chest should be obtained in children and adolescents with inhalation exposures and those with respiratory symptoms and signs (",
"    <a class=\"graphic graphic_table graphicRef64012 \" href=\"UTD.htm?34/56/35725\">",
"     table 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77266 \" href=\"UTD.htm?2/37/2653\">",
"     table 22",
"    </a>",
"    ). Radiographs also may be obtained to search for concomitant injury and to confirm the placement of endotracheal tubes, nasogastric tubes, and central lines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, certain radiopaque toxins, including packets of illicit drugs smuggled internally by body packers, may be visualized by plain film radiographs (",
"    <a class=\"graphic graphic_table graphicRef50965 \" href=\"UTD.htm?36/8/37003\">",
"     table 23",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68584 \" href=\"UTD.htm?27/43/28350\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78845 \" href=\"UTD.htm?41/2/42030\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Computed tomography (CT) has little utility in the diagnosis of poisoning. However, CT of the head can be useful in identifying injuries from or complications of poisoning such as intracranial hemorrhage (eg, in cocaine intoxication) or cerebral edema as a complication of hypoxemia; abdominal CT can also be useful in the evaluation of body packers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of the poisoned child depends upon the specific poison(s) involved, the presenting and predicted severity of illness, and elapsed time between exposure and presentation. Supportive care is the mainstay of therapy, which variably involves decontamination, antidotal therapy, and enhanced elimination techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is the most important aspect of treatment and, when coupled with decontamination, is usually sufficient for complete recovery. Supportive care for toxic exposures is similar to that provided for other problems, but certain issues are managed slightly differently:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway protection by endotracheal intubation should be performed early in the poisoned patient with depressed mental status because of the high risk for aspiration and its associated complications, particularly when gastric decontamination is necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/55\">",
"       55",
"      </a>",
"      ]. Endotracheal intubation with mechanical ventilation is also indicated for severe acid-base disturbances or acute respiratory failure. In addition, mechanical ventilation may be necessary in patients who require sedation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paralysis to limit the extent of complications such as hyperthermia, acidosis, and rhabdomyolysis.",
"     </li>",
"     <li>",
"      Hypotension should be managed initially with intravenous fluids. Vasopressors are required when hypotension does not resolve with volume expansion. Direct-acting vasopressors, such as norepinephrine, have been shown to be more effective than indirect-acting agents, such as dopamine, when tricyclic antidepressants have been ingested [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"       \"Tricyclic antidepressant poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension in agitated patients is best treated initially with nonspecific sedatives such as a benzodiazepine [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/58\">",
"       58",
"      </a>",
"      ]. When hypertension necessitates specific therapy because of associated end-organ dysfunction, preferred treatments are",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"       esmolol",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/36/14917?source=see_link\">",
"       phentolamine",
"      </a>",
"      . The use of beta-blockers alone for patients with sympathetic hyperactivity (eg, cocaine intoxication) is",
"      <strong>",
"       not",
"      </strong>",
"      recommended because it may result in unopposed alpha-adrenergic stimulation and intensified vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. Short acting agents are generally preferred because they are easily titrated.",
"     </li>",
"     <li>",
"      Ventricular tachycardias are usually treated with standard Advanced Cardiac Life Support (ACLS) or Pediatric Advanced Life Support (PALS) recommendations:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      , and cardioversion or defibrillation. However, when ventricular tachycardias occur in the context of intoxication with tricyclic antidepressants or other membrane-active agents,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      is the first-line therapy. Treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      , overdrive pacing with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/25/38291?source=see_link\">",
"       isoproterenol",
"      </a>",
"      , or a temporary pacemaker may be effective in patients with drug-induced torsades de pointes and prolonged QT intervals on electrocardiogram (ECG). Digoxin-poisoned patients with life-threatening tachyarrhythmias or bradyarrhythmias should be treated with specific Fab fragments (Digibind). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"       \"Digitalis (cardiac glycoside) poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bradyarrhythmias associated with hypotension should be treated in the standard fashion with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      or temporary pacing. However, in patients with calcium channel blocker or beta blocker intoxication, the administration of calcium and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      may obviate the need for further measures [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/60-64\">",
"       60-64",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31736?source=see_link\">",
"       \"Calcium channel blocker poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"       \"Major side effects of beta blockers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizures are typically treated with benzodiazepines followed by barbiturates if necessary.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       Phenytoin",
"      </a>",
"      may be effective in controlling seizures caused by agents that stabilize neuronal membranes (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"       propranolol",
"      </a>",
"      ), but is not indicated in most poisonings and is potentially harmful in seizures resulting from",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=see_link\">",
"       theophylline",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/64\">",
"       64",
"      </a>",
"      ]. Seizures caused by certain agents may require specific antidotes for their successful termination (eg, pyridoxine for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"       isoniazid",
"      </a>",
"      toxicity, glucose for hypoglycemic agents). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"       \"Management of status epilepticus in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-associated agitation is usually treated with benzodiazepines, supplemented with high potency neuroleptics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"       haloperidol",
"      </a>",
"      ) as needed [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/65\">",
"       65",
"      </a>",
"      ]. Agitation associated with certain toxidromes may be best treated with specific agents (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/52/9028?source=see_link\">",
"       physostigmine",
"      </a>",
"      for the anticholinergic syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/66\">",
"       66",
"      </a>",
"      ]. (See appropriate topic reviews).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initial patient stabilization, patient decontamination is a priority. The sooner decontamination is performed, the more effective it is at preventing poison absorption. Decontamination of poisoned children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    has become the",
"    <strong>",
"     preferred method",
"    </strong>",
"    of GI decontamination in children. The use of activated charcoal is controversial in the asymptomatic patient. If activated charcoal is to be administered, voluntary ingestion in the alert and cooperative patient is preferred to nasogastric administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H10032467#H10032467\">",
"     \"Decontamination of poisoned children\", section on 'Activated charcoal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical benefit of gastric lavage has not been confirmed in controlled studies, and its routine use in the management of poisoned patients is",
"    <strong>",
"     no longer recommended",
"    </strong>",
"    by the American Academy of Clinical Toxicology or the European Association of Poisons Centres and Clinical Toxicologists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H9#H9\">",
"     \"Decontamination of poisoned children\", section on 'Gastric lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whole bowel irrigation is another technique that may be considered for patients who have ingested large amounts of substances that are not well bound to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef77553 \" href=\"UTD.htm?4/37/4700\">",
"     table 24",
"    </a>",
"    ), sustained release preparations, and illicit drug packets [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H21#H21\">",
"     \"Decontamination of poisoned children\", section on 'Whole bowel irrigation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Antidotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidote administration is appropriate when there is a poisoning for which an antidote exists, the actual or predicted severity of poisoning warrants its use, expected benefits of therapy outweigh its associated risk, and there are no contraindications. Antidotes reduce or reverse poison effects by a variety of means. They may prevent absorption, bind and neutralize poisons directly, antagonize end-organ effects, or inhibit conversion to more toxic metabolites. The pediatric doses for antidotes recommended for stocking in hospitals that accept emergency admissions are listed in Table 2 (",
"    <a class=\"graphic graphic_table graphicRef70409 graphicRef81720 \" href=\"UTD.htm?41/17/42269\">",
"     table 25A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/11,13\">",
"     11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacokinetics of the intoxicant and the antidote must be considered because the toxidrome may recur if the antidote is eliminated more rapidly than the ingested substance, particularly if the antidote acts by antagonizing end-organ effects or inhibiting conversion to toxic metabolites. As an example, somnolence and respiratory depression due to ingested opiates acutely reverse with the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"     naloxone",
"    </a>",
"    but recur in approximately one-third of cases because the elimination half-life of naloxone is only 60 to 90 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=see_link\">",
"     \"Opioid intoxication in children and adolescents\"",
"    </a>",
"    .) Thus, in certain situations antidotes may require repeated administration or continuous infusion.",
"   </p>",
"   <p>",
"    The risks and benefits of antidote administration also must be carefully weighed in the setting of multiple drug ingestion. Many antidotes (eg, antivenom, chelating agents, N-acetylcysteine) may be used concurrently without adverse effects. However, notable exceptions exist. When drugs that have opposite effects are taken at the same time, the reversal of one agent may unmask the toxicity of another. As an example, in a patient who ingested",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    and cocaine, the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/58/38821?source=see_link\">",
"     flumazenil",
"    </a>",
"    , the benzodiazepine antidote, could lower the seizure threshold and increase the risk of serious complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, when drugs that have similar effects are co-ingested, the antidote may not seem to have any effect. This is a common problem when opiates are ingested with large amounts of ethanol. In such circumstances,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"     naloxone",
"    </a>",
"    may be administered in such large amounts that it results in opiate withdrawal. For this reason, naloxone should be administered at lower doses in patients in whom there is a suspicion of opiate dependence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20103?source=see_link\">",
"     \"Opioid withdrawal in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Diagnostic trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, the clinical response to an antidote may suggest the etiology of poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/23\">",
"     23",
"    </a>",
"    ]. Antidotes should be used in selected clinical scenarios by clinicians who are experienced in their use, or after consultation with available experts such as those at regional Poison Control Centers (1-800-222-1222). Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improved alertness in response to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/58/38821?source=see_link\">",
"       flumazenil",
"      </a>",
"      for benzodiazepine ingestion; flumazenil is contraindicated in drug ingestions that may precipitate seizures and in patients with a known seizure disorder. It also may precipitate withdrawal in patients with benzodiazepine dependence.",
"     </li>",
"     <li>",
"      Improved alertness in response to glucose for insulin or oral hypoglycemic agent ingestion.",
"     </li>",
"     <li>",
"      Improved alertness in response to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/52/9028?source=see_link\">",
"       physostigmine",
"      </a>",
"      for anticholinergic agent ingestion; physostigmine is contraindicated in tricyclic antidepressant overdoses. Physostigmine should not be administered to patients who have a widened QRS interval on electrocardiogram.",
"     </li>",
"     <li>",
"      Improved alertness in response to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"       naloxone",
"      </a>",
"      for opiate ingestion.",
"     </li>",
"     <li>",
"      Improved clotting in response to protamine for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      overdoses.",
"     </li>",
"     <li>",
"      Abatement of dystonia in response to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      for phenothiazine ingestion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Enhanced elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced elimination techniques can be used for several drugs and toxins (",
"    <a class=\"graphic graphic_table graphicRef66414 \" href=\"UTD.htm?23/0/23564\">",
"     table 26",
"    </a>",
"    ). Enhanced elimination techniques are discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initial evaluation, treatment, and a short period of observation, disposition of the patient is based upon the observed and predicted severity of toxicity. Patients who develop only mild toxicity and who have only a low predicted severity can be observed in the emergency department until they are asymptomatic. An observation period of six hours is usually adequate for this purpose.",
"    <strong>",
"     All",
"    </strong>",
"    patients with intentional overdose require psychiatric assessment prior to discharge.",
"   </p>",
"   <p>",
"    Other factors to consider in the disposition include whether the child's caregivers understand the potential for delayed consequences of poisoning, have a means of transportation to return if necessary, and are able to provide adequate observation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/60/22474/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, if suboptimal home environment contributed to the ingestion, consultation with a social worker may be indicated, particularly if child neglect is being considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=see_link\">",
"     \"Child neglect and emotional abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Longer observation (or hospital admission) may be necessary for patients who are thought to have ingested substances with delayed effects (",
"    <a class=\"graphic graphic_table graphicRef55219 \" href=\"UTD.htm?8/2/8237\">",
"     table 7",
"    </a>",
"    ), sustained release preparations, or multiple agents. The duration of observation varies depending upon the expected time of onset and duration of symptoms. The half-lives of drugs are calculated based upon therapeutic dosing; in the overdose setting, the calculated half-life may be inaccurate and the duration of symptoms prolonged",
"   </p>",
"   <p>",
"    The toxicity of agents varies depending upon whether the ingestion is acute or chronic, whether other substances have been ingested, the time between ingestion and presentation, and the child's baseline health status. Thus, decisions regarding admission should be based both on drug levels and the clinical scenario.",
"   </p>",
"   <p>",
"    Patients with moderate observed toxicity or those who are at risk for such on the basis of history or initial laboratory data should be admitted to an intermediate care floor or an appropriate observation unit for continued monitoring and treatment. Patients with significant toxicity should be admitted to an ICU (",
"    <a class=\"graphic graphic_table graphicRef81467 \" href=\"UTD.htm?6/61/7132\">",
"     table 27",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional Poison Centers are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Another helpful resource is the Cornell University Poisonous Plants Informational Database (",
"    <a class=\"external\" href=\"file://www.ansci.cornell.edu/plants/index.html\">",
"     www.ansci.cornell.edu/plants/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7707187\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occult toxic exposure should be considered in the differential diagnosis of children who present with acute onset of multiorgan system dysfunction, altered mental status, respiratory or cardiac compromise, unexplained metabolic acidosis, seizures, or a puzzling clinical picture. The index of suspicion should be raised if the child is in the \"at risk\" age group (one to four years of age)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      has a previous history of poisoning. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In older children and adolescents with occult poisoning suspect suicide attempts or recreational abuse of illicit or prescription drugs. Child abuse via forced ingestion in young children also occurs, particularly in those who are younger than one year of age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to the poisoned child begins with initial evaluation and stabilization of airway, breathing, circulation, and evaluation and treatment of disability while fully exposing the patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial evaluation and stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoxemia and hypoglycemia are two common causes of altered mental status in the poisoned patient that should be promptly evaluated and addressed during initial stabilization. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial evaluation and stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"       naloxone",
"      </a>",
"      &nbsp;is indicated in patients who have depressed mental status, diminished respirations, miotic pupils, or other circumstantial evidence of opioid intoxication. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Altered mental status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      History and physical examination are helpful in determining the type of poisoning in a significant number of children. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis of poisoning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of mental status, vital signs, and pupils, along with assessment of skin and other findings (toxidrome recognition) may provide clues to the type of poisoning and help guide empiric and directed treatment (",
"      <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Key ancillary studies include rapid blood glucose, electrolytes with calculation of an anion gap, venous or arterial blood gas, serum",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      level, and electrocardiogram. Patients with respiratory alkalosis or metabolic acidosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an elevated anion gap also warrant measurement of a salicylate level and serum osmolality. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Ancillary studies'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Supportive care is the most important aspect of treatment and, when coupled with decontamination (when indicated), is usually sufficient for complete recovery. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Supportive care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antidotes should be used in selected clinical scenarios by clinicians who are experienced in their use, or after consultation with available experts such as those at regional Poison Control Centers (in the USA, 1-800-222-1222). The World Health Organization provides a listing of international poison centers at its website (",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Antidotes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/1\">",
"      Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     Osterhoudt KC, Burns Ewald M, Shannon M, Henretig FM. Toxicologic emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.951.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/3\">",
"      Bryant S, Singer J. Management of toxic exposure in children. Emerg Med Clin North Am 2003; 21:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/4\">",
"      Mofenson HC, Greensher J. The unknown poison. Pediatrics 1974; 54:336.",
"     </a>",
"    </li>",
"    <li>",
"     Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Principles of managing the poisoned or overdosed patient: An overview. In: Goldfrank's Toxicologic Emergencies, 6th, Goldfrank L.  (Ed), Appleton and Lange, Stamford 1998. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/6\">",
"      Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. American College of Emergency Physicians. Ann Emerg Med 1995; 25:570.",
"     </a>",
"    </li>",
"    <li>",
"     Linden CH. General considerations in the evaluation and treatment of poisoning. In: Intensive Care Medicine, Rippe JM, Irwin RS, Fink MP, Cerra FB.  (Eds), Little Brown and Company, Boston 1996. p.1455.",
"    </li>",
"    <li>",
"     Clancy C. Electrocardiographic evaluation of the poisoned or overdosed patient. In: Goldfrank's Toxicologic Emergencies, 6th, Goldfrank L, et al.  (Eds), Appleton and Lange, Stamford 1998. p.1105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/9\">",
"      Boehnert MT, Lovejoy FH Jr. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985; 313:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/10\">",
"      Kirk M, Pace S. Pearls, pitfalls, and updates in toxicology. Emerg Med Clin North Am 1997; 15:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/11\">",
"      Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1999; 33:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/12\">",
"      Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. JAMA 1995; 274:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/13\">",
"      Dart RC, Goldfrank LR, Chyka PA, et al. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 2000; 36:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/14\">",
"      Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986; 15:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/15\">",
"      Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med 1991; 20:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/16\">",
"      Tate JR, Nixon PF. Measurement of Michaelis constant for human erythrocyte transketolase and thiamin diphosphate. Anal Biochem 1987; 160:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/17\">",
"      Emery, D, Singer J. Highly toxic ingestions for toddlers: when a pill can kill. Pediatr Emerg Med Rep 1998; 3:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/18\">",
"      Osterhoudt, KC. The toxic toddler: drugs that can kill in small doses. Contemp Pediatr 2000;17:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/19\">",
"      Liebelt EL, Shannon MW. Small doses, big problems: a selected review of highly toxic common medications. Pediatr Emerg Care 1993; 9:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/20\">",
"      Koren G. Medications which can kill a toddler with one tablet or teaspoonful. J Toxicol Clin Toxicol 1993; 31:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/21\">",
"      Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/22\">",
"      Shannon M. Ingestion of toxic substances by children. N Engl J Med 2000; 342:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/23\">",
"      Woolf AD. Poisoning by unknown agents. Pediatr Rev 1999; 20:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/24\">",
"      Brayden RM, MacLean WE Jr, Bonfiglio JF, Altemeier W. Behavioral antecedents of pediatric poisonings. Clin Pediatr (Phila) 1993; 32:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/25\">",
"      Soslow AR. Acute drug overdose: one hospital's experience. Ann Emerg Med 1981; 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/26\">",
"      Wright N. An assessment of the unreliability of the history given by self-poisoned patients. Clin Toxicol 1980; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/27\">",
"      Woolf A, Alpert HR, Garg A, Lesko S. Adolescent occupational toxic exposures: a national study. Arch Pediatr Adolesc Med 2001; 155:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/28\">",
"      Ratnapalan S, Potylitsina Y, Tan LH, et al. Measuring a toddler's mouthful: toxicologic considerations. J Pediatr 2003; 142:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/29\">",
"      Havlik DM, Nolte KB. Fatal \"crack\" cocaine ingestion in an infant. Am J Forensic Med Pathol 2000; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/30\">",
"      Boros CA, Parsons DW, Zoanetti GD, et al. Cannabis cookies: a cause of coma. J Paediatr Child Health 1996; 32:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/31\">",
"      Winter ML, Ellis MD, Snodgrass WR. Urine fluorescence using a Wood's lamp to detect the antifreeze additive sodium fluorescein: a qualitative adjunctive test in suspected ethylene glycol ingestions. Ann Emerg Med 1990; 19:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/32\">",
"      Fulop M. Flow diagrams for the diagnosis of acid-base disorders. J Emerg Med 1998; 16:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/33\">",
"      Rutecki GW, Whittier FC. An approach to clinical acid-base problem solving. Compr Ther 1998; 24:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/34\">",
"      Gabow PA. Disorders associated with an altered anion gap. Kidney Int 1985; 27:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/35\">",
"      Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore) 1977; 56:38.",
"     </a>",
"    </li>",
"    <li>",
"     Hoffman RS. Fluid, electrolyte, and acid-base principles. In: Goldfrank's Toxicologic Emergencies, 6th, Goldfrank L, et al.  (Eds), Appleton and Lange, Stamford 1998. p.243.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/37\">",
"      Jurado RL, del Rio C, Nassar G, et al. Low anion gap. South Med J 1998; 91:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/38\">",
"      Steinhart B. Case report: severe ethylene glycol intoxication with normal osmolal gap--\"a chilling thought\". J Emerg Med 1990; 8:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/39\">",
"      Glaser DS. Utility of the serum osmol gap in the diagnosis of methanol or ethylene glycol ingestion. Ann Emerg Med 1996; 27:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/40\">",
"      Eisen TF, Lacouture PG, Woolf A. Serum osmolality in alcohol ingestions: differences in availability among laboratories of teaching hospital, nonteaching hospital, and commercial facilities. Am J Emerg Med 1989; 7:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/41\">",
"      Hoffman RS, Smilkstein MJ, Howland MA, Goldfrank LR. Osmol gaps revisited: normal values and limitations. J Toxicol Clin Toxicol 1993; 31:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/42\">",
"      Wallace KL, Suchard JR, Curry SC, Reagan C. Diagnostic use of physicians' detection of urine fluorescence in a simulated ingestion of sodium fluorescein-containing antifreeze. Ann Emerg Med 2001; 38:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/43\">",
"      Casavant MJ, Shah MN, Battels R. Does fluorescent urine indicate antifreeze ingestion by children? Pediatrics 2001; 107:113.",
"     </a>",
"    </li>",
"    <li>",
"     Osterloh JD, Snyder JW. Laboratory principles and techniques to evaluate the poisoned or overdosed patient. In: Goldfrank's Toxicologic Emergencies, 6th, Goldfrank L, et al.  (Eds), Appleton and Lange, Stamford 1998. p.64.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/45\">",
"      Wiley JF 2nd. Difficult diagnoses in toxicology. Poisons not detected by the comprehensive drug screen. Pediatr Clin North Am 1991; 38:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/46\">",
"      Osterloh JD. Utility and reliability of emergency toxicologic testing. Emerg Med Clin North Am 1990; 8:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/47\">",
"      Litovitz TL, Klein-Schwartz W, Dyer KS, et al. 1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1998; 16:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/48\">",
"      Ashbourne JF, Olson KR, Khayam-Bashi H. Value of rapid screening for acetaminophen in all patients with intentional drug overdose. Ann Emerg Med 1989; 18:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/49\">",
"      Sporer KA, Khayam-Bashi H. Acetaminophen and salicylate serum levels in patients with suicidal ingestion or altered mental status. Am J Emerg Med 1996; 14:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/50\">",
"      Belson MG, Simon HK. Utility of comprehensive toxicologic screens in children. Am J Emerg Med 1999; 17:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/51\">",
"      Brett AS. Implications of discordance between clinical impression and toxicology analysis in drug overdose. Arch Intern Med 1988; 148:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/52\">",
"      Kellermann AL, Fihn SD, LoGerfo JP, Copass MK. Impact of drug screening in suspected overdose. Ann Emerg Med 1987; 16:1206.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartz DT. Toxicologic imaging. In: Goldfrank's Toxicologic Emergencies, 6th, Goldfrank L.  (Ed), Appleton and Lange, Stamford 1998. p.78.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/54\">",
"      Florez MV, Evans JM, Daly TR. The radiodensity of medications seen on x-ray films. Mayo Clin Proc 1998; 73:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/55\">",
"      Roy TM, Ossorio MA, Cipolla LM, et al. Pulmonary complications after tricyclic antidepressant overdose. Chest 1989; 96:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/56\">",
"      Tran TP, Panacek EA, Rhee KJ, Foulke GE. Response to dopamine vs norepinephrine in tricyclic antidepressant-induced hypotension. Acad Emerg Med 1997; 4:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/57\">",
"      Buchman AL, Dauer J, Geiderman J. The use of vasoactive agents in the treatment of refractory hypotension seen in tricyclic antidepressant overdose. J Clin Psychopharmacol 1990; 10:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/58\">",
"      Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med 1995; 333:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/59\">",
"      Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990; 112:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/60\">",
"      Kenny J. Treating overdose with calcium channel blockers. BMJ 1994; 308:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/61\">",
"      Yuan TH, Kerns WP 2nd, Tomaszewski CA, et al. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol 1999; 37:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/62\">",
"      Kline JA, Tomaszewski CA, Schroeder JD, Raymond RM. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther 1993; 267:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/63\">",
"      Kerns W 2nd, Schroeder D, Williams C, et al. Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med 1997; 29:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/64\">",
"      Blake KV, Massey KL, Hendeles L, et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med 1988; 17:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/65\">",
"      Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/66\">",
"      Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med 2000; 35:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/67\">",
"      Sporer KA. Acute heroin overdose. Ann Intern Med 1999; 130:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/60/22474/abstract/68\">",
"      Watson WA, Steele MT, Muelleman RL, Rush MD. Opioid toxicity recurrence after an initial response to naloxone. J Toxicol Clin Toxicol 1998; 36:11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6496 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-118.97.94.19-90DFCF4173-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22474=[""].join("\n");
var outline_f21_60_22474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7707187\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL EVALUATION AND STABILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Altered mental status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS OF POISONING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Blood gas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Electrolytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Serum osmolality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7707604\">",
"      - Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Toxicology screens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Antidotes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Diagnostic trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Enhanced elimination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7707187\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6496|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/43/28350\" title=\"diagnostic image 1\">",
"      Ferrous sulfate overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/2/42030\" title=\"diagnostic image 2\">",
"      Drug packet ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6496|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/20/10561\" title=\"picture 1A\">",
"      Ca oxalate monohydrate crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/19/42302\" title=\"picture 1B\">",
"      Calcium oxalate crystals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/6/44140\" title=\"table 1\">",
"      Poisoning syndromes - toxidromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/43/43708\" title=\"table 2\">",
"      Drug and toxin related hypoxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/8/29838\" title=\"table 3\">",
"      Drug and toxin related pulse changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/11/23742\" title=\"table 4\">",
"      Drug and toxin induced ECG abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/52/3918\" title=\"table 5\">",
"      Drug and toxin induced mental status changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/37/41564\" title=\"table 6\">",
"      Drug and toxin related electrolyte change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/2/8237\" title=\"table 7\">",
"      Delayed clinical toxicity agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/18/4395\" title=\"table 8\">",
"      Agents causing fatal poisoning in young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/1/15389\" title=\"table 9\">",
"      Medications and toxins fatal in small doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/12/32973\" title=\"table 10\">",
"      Drug and toxin related temperature change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/56/35725\" title=\"table 11\">",
"      Drug and toxin related respiratory change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/59/4030\" title=\"table 12\">",
"      Drug and toxin induced ocular findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/51/29501\" title=\"table 13\">",
"      Drug and toxin related skin findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/59/28606\" title=\"table 14\">",
"      Drug and toxin related movement disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/17/15643\" title=\"table 15\">",
"      Drug and toxin associated odors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/8/19598\" title=\"table 16\">",
"      Drug and toxin related laboratory changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/40/43659\" title=\"table 17\">",
"      Drug and toxin related acid base disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/3/24637\" title=\"table 18\">",
"      Drug and toxin related anion gap changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/52/6988\" title=\"table 19\">",
"      Increased osmolal and O2 gaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/57/25499\" title=\"table 20\">",
"      Urine test drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/10/3244\" title=\"table 21\">",
"      Therapeutic levels common drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/37/2653\" title=\"table 22\">",
"      Drug and toxin related pulmonary edema or pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/8/37003\" title=\"table 23\">",
"      Radiopaque toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/37/4700\" title=\"table 24\">",
"      Agents for which activated charcoal is not recommended",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/36/40524\" title=\"table 25A\">",
"      Antidotes pediatric poisoning A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/50/28460\" title=\"table 25B\">",
"      Antidotes pediatric poisoning B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/0/23564\" title=\"table 26\">",
"      Enhanced elimination drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/61/7132\" title=\"table 27\">",
"      Poisoned patient ICU criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=related_link\">",
"      Assessment of perfusion in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=related_link\">",
"      Basic life support in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31736?source=related_link\">",
"      Calcium channel blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27736?source=related_link\">",
"      Hydrocarbon poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=related_link\">",
"      Inhalant abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=related_link\">",
"      Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=related_link\">",
"      Opioid intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20103?source=related_link\">",
"      Opioid withdrawal in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=related_link\">",
"      Physiology and classification of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=related_link\">",
"      Primary drugs in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=related_link\">",
"      Serum osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_60_22475="Management of ICH after thrombolysis for ischemic stroke";
var content_f21_60_22475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of intracerebral hemorrhage after thrombolysis for ischemic stroke",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Consider bleeding the likely cause of neurologic worsening after use of a thrombolytic drug until a brain scan confirms or refutes hemorrhage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Immediately discontinue ongoing infusion of thrombolytic drug.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Obtain emergent head CT or MRI stat.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Obtain blood samples for type and crossmatch, prothrombin time, activated partial thromboplastin time, platelet count, and fibrinogen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        5. If intracerebral hemorrhage is confirmed by imaging:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Give 10 units of cryoprecipitate to increase the levels of fibrinogen and factor VIII",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Give 6 to 8 units of platelets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - In patients receiving unfractionated heparin (UFH) for any reason, consider giving 1 mg of protamine for every 100 U of UFH received in the preceding four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Obtain neurosurgical consultation and consider evacuation of the hematoma.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22475=[""].join("\n");
var outline_f21_60_22475=null;
var title_f21_60_22476="Diab prevalence youth";
var content_f21_60_22476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence and prevalence of type 1 and type 2 diabetes mellitus in US youth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Type 1 diabetes mellitus",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Type 2 diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Incidence (per 100,000 individuals annually)",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Prevalence (per 1000 individuals)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Incidence (per 100,000 individuals annually)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Prevalence (per 1000 individuals)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        0-9 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        10-19 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        0-9 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        10-19 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        10-19 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        10-19 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-hispanic white",
"       </td>",
"       <td>",
"        24.8",
"       </td>",
"       <td>",
"        22.6",
"       </td>",
"       <td>",
"        1.03",
"       </td>",
"       <td>",
"        2.89",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        0.18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        African American",
"       </td>",
"       <td>",
"        15.7",
"       </td>",
"       <td>",
"        15.7",
"       </td>",
"       <td>",
"        0.57",
"       </td>",
"       <td>",
"        2.04",
"       </td>",
"       <td>",
"        19.0",
"       </td>",
"       <td>",
"        1.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hispanic",
"       </td>",
"       <td>",
"        14.1",
"       </td>",
"       <td>",
"        13.8",
"       </td>",
"       <td>",
"        0.44",
"       </td>",
"       <td>",
"        1.59",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"       <td>",
"        0.46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asian-Pacific Islander",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        0.26",
"       </td>",
"       <td>",
"        0.77",
"       </td>",
"       <td>",
"        12.1",
"       </td>",
"       <td>",
"        0.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Navajo",
"       </td>",
"       <td>",
"        2.24",
"       </td>",
"       <td>",
"        2.97",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"       <td>",
"        0.28",
"       </td>",
"       <td>",
"        27.7",
"       </td>",
"       <td>",
"        1.45",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence rates are for incident years 2002-2005; prevalence rates are for index year 2001.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The SEARCH for diabetes in youth study. Diabetes Care 2009; 32:Supplement2.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22476=[""].join("\n");
var outline_f21_60_22476=null;
var title_f21_60_22477="Captopril lowers cardiovascular mortality post-MI";
var content_f21_60_22477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Captopril lowers cardiovascular mortality post-MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 270px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Life table for death from cardiovascular disease in 2231 patients in the SAVE trial with left ventricular dysfunction but without overt heart failure randomized to captopril or placebo 3 to 16 days after an acute myocardial infarction. Captopril significantly lowered the cardiovascular mortality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pfeffer MA, Braunwald E, Moye LA, et al. N Engl J Med 1992, 327:669.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22477=[""].join("\n");
var outline_f21_60_22477=null;
var title_f21_60_22478="Contents: Anxiety disorders";
var content_f21_60_22478=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?41/24/42381\">",
"       Psychiatry",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Anxiety disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Anxiety disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/32/11782\">",
"           Acute procedure anxiety in adults: Course, screening, assessment, and differential diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/39/9849\">",
"           Acute procedure anxiety in adults: Epidemiology and clinical presentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7080\">",
"           Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/15/10488\">",
"           Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/42/24232\">",
"           Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/41/38553\">",
"           Comorbid anxiety and depression: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/13/41177\">",
"           Co-occurring anxiety disorders and substance use disorders: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/61/30678\">",
"           Deep brain stimulation for treatment of obsessive-compulsive disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/0/32776\">",
"           Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36564\">",
"           Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42582\">",
"           Obsessive-compulsive disorder in pregnant and postpartum women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/42/44713\">",
"           Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2665\">",
"           Pharmacotherapy for generalized anxiety disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/0/23561\">",
"           Pharmacotherapy for obsessive-compulsive disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/8/7305\">",
"           Pharmacotherapy for panic disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33239\">",
"           Pharmacotherapy for posttraumatic stress disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/49/27416\">",
"           Pharmacotherapy for social anxiety disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/41/6806\">",
"           Pharmacotherapy for specific phobia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/45/27352\">",
"           Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20505\">",
"           Psychotherapy for generalized anxiety disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/37/34391\">",
"           Psychotherapy for obsessive-compulsive disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/22/40297\">",
"           Psychotherapy for panic disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/58/5032\">",
"           Psychotherapy for posttraumatic stress disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32327\">",
"           Psychotherapy for social anxiety disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/59/25527\">",
"           Psychotherapy for specific phobia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/44/44744\">",
"           Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/24/22921\">",
"           Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/0/26632\">",
"           Treatment for specific phobias of medical and dental procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/18/9512\">",
"           Treatment of acute procedure anxiety in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24197\">",
"           Treatment of acute stress disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/18/29993\">",
"           Treatment of co-occurring anxiety disorders and substance use disorders",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-D0ABD58E25-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f21_60_22478=[""].join("\n");
var outline_f21_60_22478=null;
var title_f21_60_22479="Weight specific BMR children";
var content_f21_60_22479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Weight-specific basal metabolic rate, activity energy expenditure, and total energy expenditure (MJ/kg per day) of infants and children from birth to 18 years of age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 744px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BMR: basal metabolic rate; AEE: activity energy expenditure; TEE: total energy expenditure.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Torun, B, Davies, PS, Livingstone, MB, et al. Energy requirements and dietary energy recommendations for children and adolescents 1 to 18 years old. Eur J Clin Nutr 1996; 50 Suppl 1:S37.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_60_22479=[""].join("\n");
var outline_f21_60_22479=null;
